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Abstract 
 
This thesis describes the development and optimization of a seven-plex reverse 
transcription polymerase chain reaction (RT-PCR) and corresponding user-friendly 
electronic microarray for the detection of seven swine viruses: foot-and-mouth disease, 
swine vesicular disease, classical swine fever, vesicular exanthema of swine, African 
swine fever, porcine circovirus type 2 and porcine reproductive and respiratory 
syndrome. A panel of 58 strains of the viruses were successfully amplified and detected 
specifically on the NanoChip 400 microarray system while having no detection of 22 
non-specific clinical material and non-target viruses and bacteria. Target viruses were 
also detected from clinical and biological materials spiked with viruses as early as 1 days 
post-infection. Detection limits ranged from 10 to 1000 copies for the targets. The assay 
was successfully transferred to the prototype Nexogen MDx portable and integrated 
system, where the fully automated system, with no manual handling from sample to 
detection, detected five of the seven viruses.  
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1 
Chapter 1. Molecular Tools for Veterinary Diagnostics 
 
 
1.1.0. Introduction 
The risk of invasive species being introduced into naïve ecosystems has increased 
in recent years due to the rapid increase of global trading of goods. Invasive species can 
be any organisms that are not naturally found in another geographical range. The types of 
invasive species can range from animals and plants to microorganisms and viruses. The 
introduction of a foreign virus can be devastating and lead to an epidemic that costs 
agriculture industries billions of dollars. This has been demonstrated repeatedly in the 
past, including the outbreak of classical swine fever virus (CSFV) in the Netherlands 
(Terpstra and de Smit 2000), the 2003 occurrence of bovine spongiform encephalopathy 
(BSE) in Alberta Canada (Jones and Davidson 2014), the 2010 foot-and-mouth disease 
(FMD) outbreak in Korea (J.-H. Park et al. 2013) and the emergence of the porcine 
epidemic diarrhea virus (PEDV) in the United States in 2013 (Stevenson et al. 2013).  
The World Organization for Animal Health, referred to as the OIE (Office 
International des Epizooties), is an international organization that deals with the 
improvement of animal health globally (http://www.oie.int/about-us/). The OIE acts as a 
hub of knowledge, creating an avenue for other countries to learn about possible diseases 
as well as the knowledge and expertise needed to protect against the pathogens causing 
these diseases. Their work is recognized by the World Trade Organization (WTO), 
allowing for standardized documents to be incorporated easily into other countries trade 
practices (http://www.oie.int/about-us/our-missions/). In 2018, 182 countries were listed 
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as members in the organization. These members create a network for the sharing of 
information and expertise as well as having international standards for animal welfare as 
well as trade standards with the WTO (http://www.oie.int/animal-welfare/oie-standards-
and-international-trade/). These international standards are taken up by the member 
countries and administered by organizations such as the Canadian Food Inspection 
Agency (CFIA). Organizations such as the CFIA implement surveillance and diagnostic 
testing of the most harmful veterinary pathogens that can damage a country’s economy 
by following the OIE standards. In 2001 the foot-and-mouth disease virus (FMDV)  
caused a massive outbreak in the United Kingdom (UK) resulting in approximately $13 
billion USD  in losses to producers, as well as 6.5 million animals being destroyed as a 
result of direct or indirect contact with infected farms (Thompson et al. 2002). Outbreaks 
such as this are the reason that world reference laboratories (WRL) such as the Pirbright 
Institute in the UK and the CFIA National Centre for Animal Diseases (NCAD) and 
National Centre for Foreign Animal Diseases (NCFAD) exist. The individual scientists at 
these WRLs, experts in their own fields, are who apply to the OIE to become a reference 
lab. These experts are required to be actively pursuing research in their field and are 
responsible for the assistance, both scientific and technical, to any other lab or member 
country that inquires assistance with their respective pathogen. Of the many 
responsibilities of WRLs, researchers must collect, store and distribute information and 
biological materials, as well as provide scientific and/or technical training for 
representatives from other member countries (http://www.oie.int/scientific-
expertise/reference-laboratories/terms-of-reference/). The CFIA has multiple WRL 
experts that cover a range of diseases from anthrax to trichinellosis (Table 1). It is the 
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responsibility of individuals, such as Dr. Oliver Lung and Dr. Kingsley Amoako, to be a 
resource for advice and support in the surveillance, troubleshooting problems other 
groups may be having with their respective disease and report on their activities to the 
OIE.   
 
1.2.0. Gold Standard Testing for High Consequence Pathogens 
 
Viruses such as FMDV, CSFV, swine vesicular disease virus (SVDV), African 
swine fever virus (ASFV) and vesicular exanthema of swine virus (VESV) are all listed 
as federally reportable diseases by the OIE (“Federally Reportable Diseases for 
Terrestrial Animals in Canada - 2014” 2014) and can be considered  high consequence 
pathogens due to their contagious nature and/or their indistinguishable symptomology. 
Any cases of these diseases found should be reported to the government and samples sent 
away for diagnostic confirmation at a licensed laboratory equipped to handle the 
appropriate risk group microoganisms and viruses. If during the diagnosis process any 
issues arise, such as failure to grow in culture or detection is weak or non-existent due to 
unknown serotypes, the corresponding WRL can be contacted for support and called 
upon to confirm any test results.  One issue that can require additional confirmation is 
when symptomologies of two or more diseases are indistinguishable from one another. 
An example of this is the confounding clinical signs of FMDV and SVDV, both of which 
produce vesicular lesions on the foot and mouth of the animal (Fernández et al. 2008; 
Zimmerman et al. 2012, 603). By using laboratory testing, such as virus isolation (VI) 
and enzyme-linked immunosorbent assays (ELISA), technicians can determine whether 
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or not the pathogen is indeed present; helping to choose the best method for containment 
and management. Each of these diseases have multiple diagnostic tests that are outlined 
in “Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds and 
bees)” which describes all the prescribed test methods used (OIE - World Organization 
for Animal Health 2018, http://www.oie.int/standard-setting/terrestrial-manual/access-
online/).   
The OIE can prescribe many different tests for pathogens from complement 
fixation, virus neutralization, VI, ELISA and real-time PCR (qPCR) for FMDV (OIE - 
World Organization for Animal Health 2013, chap. 2.1.8.). Though not all of the 
prescribed tests are often used, the ones that are most commonly used can be referred to 
as “Gold Standard Tests” (GST). Tests such as VI have GST status due to its high  usage 
in diagnostic tests (D Deregt and Prins 1998; Ferris and Dawson 1988; Mittelholzer et al. 
2006; Oka et al. 2014).  
Though not all GSTs are validated according to OIE specifications, some are able 
to be validated into the OIE system after going through a rigorous testing process. The 
simplified development and validation pathway in Figure 1, referred from chapter 1.1.6 
of the OIE diagnostic manual, defines the steps involved in validating a new diagnostic 
assay for use as an OIE GST. Any potential diagnostic test under evaluation must follow 
each category and meet each criterion. Gold standard tests are then implemented at 
appropriate WRL labs and other institutions where they can fulfill their mandate. The 
final purpose of OIE GSTs is to determine the absence of disease causing pathogens in 
geographical areas/countries, certify the health of animals bound for export/import, and 
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aid in eradication of the target pathogens (OIE - World Organization for Animal Health 
2013, chap. 1.1.6.)  
Gold standard tests are required to maintain a number of important characteristics. 
These characteristics include but are not limited to: Reproducibility, sensitivity, 
specificity and inclusivity. Repoducibility is required for all scientific work as it gives 
credibility to the project. If the work that is done cannot be reproduced in another 
laboratory setting, then the assay itself is called into question. A GST must be able to be 
transported from one diagnostic laboratory to another diagnostic laboratory, and be able 
to produce the same results. Selectivity and sensitivity refer to the ability of an assay to 
detect only the targeted organism and the lower limit of detection of the analyte, 
respectively (OIE - World Organization for Animal Health 2013; Thrusfield 2007). Most 
diagnostic tests are designed to detect and differentiate one target organism from related 
organisms or viruses. Each type of GST is designed to be specific, such as VI where each 
virus is grown in a particular medium and cell line. In cases such as the detection of 
FMDV, assays may have to be inclusive as well, being able to detect all possible 
serotypes of FMDV. FMDV has seven antigenic serotypes: A, O, C, Asia1, SAT 1, SAT 
2 and SAT 3 that produce different surface antigens that can make them distinct in terms 
of how to vaccinate against one particular serotype (OIE - World Organization for 
Animal Health 2012, vol. 1, chap. 2.1.8). Inclusivity then can be an important tool in 
developing assays that detect not only multiple pathogens but multiple strains of  
organisms such as FMDV, SVDV and vesicular stomatitis virus (Lung et al. 2011).    
The OIE GSTs have broad purposes. They help maintain statis quo in the 
economy, global trade and aid in epidemiological analysis’. Using the OIE standards, the 
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downstream users have readily available protocols, making trade and surveillance more 
streamlined. Methods such as VI, ELISA, qPCR and DNA microarrays are all useful 
tools for the detection of harmful pathogens. 
 
1.3.0. Gold Standard Testing methods 
1.3.1. Virus Isolation 
 
Virus isolation is used as a standard protocol (Reid et al. 2003; Shaw et al. 2004) 
for virus research and diagnostics. The ability to infect a cell line with a known or 
unknown virus and maintain the growth in a cell line aids research by allowing scientists 
to work with viruses in a controlled environment. Emerging or transboundary pathogens 
challenge researchers to find and isolate the target pathogen in order to study it. In 2013, 
the PEDV was discovered in U.S. swine. PEDV is a contagious swine virus that causes 
watery diarrhea, dehydration, vomiting and has a 95% mortality rate in piglets (Stevenson 
et al. 2013; Chen et al. 2014). Using VI techniques, Qi Chen (2014) was successful in 
propagating the first example of the highly virulent PEDV strain (Oka et al. 2014).  
 
1.3.2. Enzyme-linked Immunosorbant Assay 
 
Alongside VI,  ELISA is a commonly used GST. ELISA tests utilize 
immunochemistry to detect target antigens. Using antibodies, a body’s immune-response 
to a foreign antigen, the user can detect target antigens by fixing antibodies to solid 
surfaces where the antigen can then bind and detected either directly or indirectly with 
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colorimetric substrates. The OIE include indirect capture ELISA as a recommended test 
for the detection and serotyping of FMDV (OIE - World Organization for Animal Health 
2013,_chaps._2.1.8.;_http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.0
1.08_FMD.pdf). Although using ELISA to detect the presence of FMDV in afflicted 
countries can also have a major drawback when utilized in areas that are currently FMDV 
free due to vaccine usage. Animals that have been infected can be almost 
indistinguishable from those vaccinated when being tested by ELISA. Vaccination of 
FMDV can inadvertently lead to the animal becoming persistently infected, which also 
leads to un-diagnosable ELISA results compared to infections (Mackay et al. 1998). To 
combat this, researchers found that in the case of a vaccinated versus non-vaccinated 
inoculations, the virus induced antibodies to the non-structural proteins (NSP) in its host 
and the NSP can be used to detect the infection status in a herd; whether or not the herd is 
clean, infected or vaccinated with or without a persistent infection (Mackay et al. 1998). 
Since this discovery, many groups have developed assays for the detection and 
differentiation of FMDV infected and vaccinated animals (Brocchi et al. 2006; Jaworski 
et al. 2011; Sørensen et al. 1998), in the effort to eradicate FMDV and create a disease 
free status for the afflicted country. 
 
1.3.3. Nucleic Acid Tests 
 
With the surveillance of invasive pathogens, the titre of the pathogen found inside 
the host organism can be too low to cause visual symptoms, allowing an infected host 
into a naïve ecosystem. More sensitive tests are needed to mitigate these situations. 
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Nucleic acid tests are a more sensitive alternative to serology tests such as ELISA 
(Mukasa et al. 2016; Reid et al. 2003; Shaw et al. 2004). PCR is capable of amplifying a 
target gene sequence billions of times, making even low quantity analytes detectable. 
With the introduction of fluorescent probes, instruments are now able to read the PCR 
amplification of a sample in real time and are able to calculate the quantity of target 
genetic material used in the sample. Real-time PCR has been used in detection of 
different pathogens from plant fungi (Vandemark et al. 2002; Willsey et al. 2018) to 
cattle viruses (Baxi et al. 2006; Carrillo et al. 2010; Hole et al 2006; Oem et al. 2005). 
Currently, qPCR has been used as the GST for the detection of FMD due to its ability to 
accurately detect low copies of viral genomes (Shaw et al. 2007; Oem et al. 2005; King et 
al. 2006). In cases such as the work from Galvin et al., (2014) qPCR was seen to detect 
equine influenza a full day post infection (dpi) earlier than ELISA, as well as able to 
detect 100% of positive samples while VI and ELISA detected only 69 and 2% 
respectively from post-experimentally infected horses.     
 
1.3.4. Microarray 
 
Besides qPCR, microarrays are another molecular technique that offer a more 
robust approach to detection using fluorophores. DNA microarrays are platforms that use 
oligonucleotide “capture probes” that, when fixed to a solid substrate surface, can anneal 
to nucleotide sequence specific “targets”. Microarray systems have the advantage of 
being able to use hundreds if not thousands of capture probes, each bound to specific 
testing sites on the substrate, that are used to detect multiple targets simultaneously 
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(Chang et al. 2012; Ojha and Kostrzynska 2008). Slide microarrays can contain 
thousands of probes and can be replicated multiple times on the substrate surface. Cases 
such as the detection of vesicular disease viruses, with the aid of multiplex reverse 
transcription PCR (RT-PCR), were able to not only detect the individual target viruses, 
but also to differentiate between the subtypes of both FMDV and other viruses that cause 
vesicular diseases (Lung et al. 2011). Electronic microarrays use an electric current to 
speed up hybridization. Given the negative charge on nucleic acids, using an electric 
current pulls the DNA towards the positively charged pads containing the capture probes. 
This gives the technique a unique advantage by reducing the time needed for 
hybridization from at least 16 hours (Wang and Li 2011) to a few seconds (Lung et al. 
2012; Erickson et al. 2017). Microarray technologies have a distinct advantage in their 
detection ability. By utilizing multiple capture probes, inclusive assays can be developed. 
Using an example from Lung et al., (2012) Avian influenzia virus (AIV) can be detected 
and subtyped down to the specific hemagglutinin (HA) and neuraminidase (NA) subtype. 
The number of non-specific cross reactions between the different isolates was seen as 
specific enough that only one cross-reactivity between HA3 and NA8 probes was 
observed (Lung et al. 2012). An assay such as this makes it possible to detect dual 
infections of two or more isolates of the AIV as well as other pathogens (Lung et al. 
2017).   
Though VI, ELISA and qPCR are commonly used, they all have their 
disadvantages. Time, cost, infrastructure  and technical support are limitations of each 
test. VI is a time consuming process that requires specialized lab spaces, equipment and 
skilled personnel to achieve results. Traditional microarrays can also be time consuming 
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as well as requiring a skilled technician to perform steps such as the fluorescent labeling 
of the DNA target for visualization after hybridization to the capture probes (Baxi et al. 
2006; Lung et al. 2011). 
1.4.0. Automated Diagnostic Methods 
 
In the persuit of more rapid results, automation of assays have gained popularity. 
Examples of some automated systems are point-of-care (POC, or sample-to-answer) 
systems. Point-of-Care systems combine multiple components of the diagnosis process, 
for example, sample extraction, reverse transcription-PCR (RT-PCR) and detection, into 
one instrument. This cuts down greatly on the need for manual manipulation of samples 
and test materials, which reduces user error and variability, and chances of contamination 
of the sample leading to the generation of false positives. These systems can have a great 
range of operation, including partially automated and fully automated assays. Partially 
integrated assays use two of the three steps described above in combination: Front-end 
(extraction and PCR) and back-end (PCR and detection). In both cases, one step needs to 
happen in-lab, in the case of Jeslin Tan’s work on tropical disease, the pathogens were 
extracted in-lab and then run on the PCR/RT-PCR Lab-on-Chip microarray system (Tan 
et al. 2014). The advantage of the Lab-on-Chip system is its ability to incorporate 
multiple targets into one assay, giving a thorough confirmation to the causative agent. 
Many different types of POC have been developed, ranging from back end PCR/detection 
assays (Teo et al. 2011) to fully integrated systems like the EncompassMDx™ 
workstation (Lung et al. 2018; Spizz et al. 2012, 2015). In the recent work of Chen et al. 
(2016), they described the use of the Encompass MdX SOLO instrument to detect 
antibodies and viral RNA of the human immunodeficiency virus (HIV) from saliva and 
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blood samples. Testing showed that the automated MdX SOLO was able to detect viral 
titres out to 2.5x103 viral particles / mL with the on-board real-time system as well as 
being able to determine an extraction buffer that would allow for DNA extraction while 
not harming the protein antibodies for the secondary extraction of proteins (Chen and 
Zhu 2016). Instruments such as this are the future for medical care, allowing either 
hospital or veterinarian clinics to analyze patient samples on-site in an attempt to reduce 
the time needed for an accurate diagnosis. Development of new POC instruments is 
ongoing with many companies, such as Nexogen Inc. (San Diego, USA), 
SavyonDiagnostics (Ashdod, Israel), AdorDiagnostics (Rome, Italy), Abaxis (Union city, 
USA) and Roche Diagnostics (Risch-Rotkreuz, Switzerland). These companies, and 
many others, are working to create tests that incorporate all aspects of the diagnostic 
process to create instruments that save both time and labour.    
 
1.4.1. Next Generation Sequencing  
 
NGS is a powerful technique for genome sequencing. Wright et al (2011) used 
NGS to delve deeply into the microevolution of the FMD viral genome in an attempt to 
understand rapid viral RNA evolution (Wright et al. 2011). Emerging viruses such as 
PEDV are more troublesome due to the inability to propagate using VI techniques. 
During the 2013 outbreak in the U.S., PEDV was identified and propagated for the first 
time, allowing scientists to study this infectious pathogen. NGS was used as a 
confirmatory tool to identify the strain of PEDV that was involved in the outbreak 
(Stevenson et al. 2013; Chen et al. 2014). Work such as this has a goal of detecting not 
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only the target pathogen, but also other more opportunistic secondary pathogens. 
Thorburn et al. (2015) used NGS to identify multiple pathogens from upper respiratory 
infections of human patients from Influenza A HA3NA2 to Human coronavirus 
(Thorburn et al. 2015). 
Further advancements in the field of nucleic acid sequencing have also given rise 
to a third generation of NGS instruments that are capable of increasing throughput by 
sequencing single molecules as well as giving the results in real time (Granberg et al. 
2016; Greninger et al. 2015; Quick et al. 2016). One particular instrument, the MinION 
(Oxford Nanopore Technologies, Oxford, UK), utilizes a protein nanopore where single 
stranded DNA is passed through at 30 bases per second using an electrical current. In this 
instrucment, different nucleotides are detected by changes in ionic flow (Butt et al. 2018; 
Quick et al. 2016). Another strength of the Nanopore system is long read lengths, from 5 
to 50 kb, being generated and the speed at which data can be acquired in real time (Butt 
et al. 2018; Greninger et al. 2015; Quick et al. 2016). During the 2015 Ebola virus 
(EBOV) outbreak in West Africa, a mobile sequencing laboratory was set up to process 
samples received for EBOV testing. Testing showed that results could be generated in 
under an hour with no false positives found (Quick et al. 2016). The longer reads of the 
MinION, while being critical for specific identification of targets, is hindered by a high 
error rate (between 5 & 30%). This is mitigated by running multiple replicate sequences 
and creating a consensus from a pairwise alignment, increasing the accuracy to as high as 
90% (Butt et al. 2018).  
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1.5.0. Thesis Objectives  
 
Though many of these tests focus primarily on detection, they give a foundation 
for other tests that can be useful in controlling outbreaks. The use of GSTs continues to 
improve by either increasing the sensitivity of a particular test, using multiple tests in 
combination to account for weaknesses in each test or by incorporating new techniques 
that either reduce the work load and/or increase the speed of detection using integrated 
platforms or vastly increase the level of detection by sequencing the samples, showing 
distinct strains and serotypes. The constant improvement of GST, in support of food and 
animal disease surveillance, will aid in the growth of the Canadian economy by reducing 
the number of major outbreaks that occur or by helping to mitigate outbreaks that may 
negatively impact the economy.  
The work done in this thesis represents a step towards reducing work load and the 
integratation of platforms. There are two main objectives for this thesis. One, is the 
development of a multiplex RT-PCR assay on a user-friendly electronic microarray 
which will demonstrate the usefulness of automating the back-end of the diagnostic 
process (Chapter 2). It also illustrates the advantages of multiplexing multiple pathogen 
detection tests into one assay, creating a test to simultaneously detect a number of 
pathogens at once. The secondary objective will be to transfer the multiplex assay onto a 
fully integrated system, combining all major steps in the diagnosis process from 
extraction to detection. The integrated system is a collaborative effort with developers 
that wanted to create a test to fit their POC instrument (Chapter 3). This work adds to the 
knowledge base for pathogen detection by giving an account of the work done using my 
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selected pathogens and will promote future work in the field of veterinary diagnostics and 
POC assay development.  
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1.6.0. Figure Legend: 
 
Figure 1.1. OIE assay validation pathway including criteria in bullet form (OIE – World 
Organization for Animal Health 2012, vol. 1, Chp. 1.1.6).The main pathway is broken down into 
three phases: Assay development,  validation and status retention. Respective goals and objective 
are listed to the right, outlining at each step what is expected of developers.  
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Chapter 2. Development and Optimization of a User-Friendly Electronic 
Microarray Detecting Seven Swine Viruses1 
 
2.1.0. Introduction 
 
The red meat industry (eg. cattle, lamb, pork) is one of the largest industries in 
Canada, averaging approximately $6.1 billion annual domestic exports in 2017 (Statistics 
Canada 2018). Pork accounts for approximately 25% of the whole production of red meat 
totalling $4.1 billion in sales, and about 70% of all processed meats in Canada are made 
of pork (Negrave 2014). In 2011, Canada ranked as the fifth largest pork exporter 
(Brisson 2014), and in 2017 Canadian pork exports peaked at $4.2 billion (Statistics 
Canada 2018).  
Animal health is an important issue affecting the livestock industry. Disease 
outbreaks may cause huge economic losses due to reduced growth and general health that 
makes the pigs unmarketable, have lower market value, much higher pharmaceutical 
costs and increased mortality. In 2005, the United States (US) attributed $561 million in 
loss caused by diseases such as porcine reproductive and respiratory syndrome virus 
(PRRSV) (Holtkamp et al. 2013), while in 2001 in the UK, an outbreak of foot-and-
mouth disease (FMD) was responsible for losses upwards of $13 billion US (Thompson 
                                                          
1 Pulished in: “Erickson, A., M. Fisher, T. Furukawa-Stoffer, A. Ambagala, D. Hodko, J. Pasick, 
D. P. King, C. Nfon, R. Ortega Polo, and O. Lung. 2017. “A Multiplex Reverse Transcription 
PCR and Automated Electronic Microarray Assay for Detection and Differentiation of Seven 
Viruses Affecting Swine.” Transboundary and Emerging Diseases, November. 
https://doi.org/10.1111/tbed.12749.” Anthony Erickson was the lead researcher in the project, 
conceptualizing and running all the experiments, as well as supporting work done in the 
Winnipeg laboratory.  
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et al. 2002). Losses such as these are made worse by reductions and embargos on trade 
with other countries during and after outbreaks. Early detection is thus important in 
mitigating potentially devastating diseases from decimating our livestock populations and 
harming our economy. 
Foreign animal diseases (FAD) pose a great risk to economic stability as well as 
native or indigenous species (Thompson et al. 2002; Dirk Deregt et al. 2006) and also 
affects food security. FAD viruses can be highly contagious and may be easily 
transmitted through livestock populations, making surveillance of such diseases 
imperative. Many pathogens, regardless of genus or family, can cause diseases that 
cannot be readily distinguished by clinical signs and require laboratory testing for an 
accurate diagnosis. The viruses described here all have the potential for confounding 
initial diagnosis due to similar and/or identical clinical signs (Table 1). This study focuses 
on five high consequence viruses that are not currently observed in Canada and two 
differential viruses observed in Canada.  
Foot-and-mouth disease virus (FMDV), a member of the Picornaviridae family, 
is the most contagious animal virus, causing vesicular lesions in the mouth and hoofs of 
most cloven-hoofed animals including: cattle, horses, swine, sheep and all wild 
ruminants. (Lung et al. 2011; Zimmerman et al. 2012, 590; Fernández et al. 2008; Knipe 
et al. 2007). Swine vesicular disease virus (SVDV), also a member of the Picornaviridae 
family, is similar to FMDV where affected pigs also generate vesicular lesions 
(Zimmerman et al. 2012, 603; Knipe et al. 2007). Vesicular exanthema of swine virus 
(VESV), was a virus derived from feeding pigs seal meat contaminated with the San 
Miguel sea lion virus (SMSV) (Zimmerman et al. 2012, 493–94) from the Caliciviridae 
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family. Though VESV is considered an extinct virus, it is included in analysis because it 
can cause clinical signs that closely resemble clinical FMDV and SVDV cases 
(Zimmerman et al. 2012, 494).  
Another highly contagious virus is the classical swine fever virus (CSFV). 
Belonging to the Flaviviridae family, CSFV causes hemorrhages in pigs (Giammarioli et 
al. 2008) and lesions in less severe cases (Zimmerman et al. 2012, 541–42). The African 
swine fever virus (ASFV), the only member of the Asfarviridae family, can be 
misdiagnosed as a CSFV infection due to similar hemorrhagic clinical signs (Costard et 
al. 2009; Giammarioli et al. 2008).  
All five of the FAD viruses are responsible for significant economic disturbances 
throughout the globe. A CSFV outbreak in the Netherlands in 1997-1998 (Terpstra and 
de Smit 2000), the FMDV outbreaks in; the UK in 2001 (Thompson et al. 2002), Japan in 
2010 (Muroga et al. 2012) and multiple outbreaks in South Korea from 2000-2011 (Joo et 
al. 2002; J.-H. Park et al. 2013) are but a few of the examples of past outbreaks. Each one 
of these outbreak events caused great economic losses ranging from $550 million to 13 
billion. These viruses are all considered federally reportable diseases in Canada and by 
the World Organization for Animal Health, referred to as the OIE (International Office of 
Epizootics, “Federally Reportable Diseases for Terrestrial Animals in Canada - 2014” 
2014). Their status is due to their potential impact on global trade, making these FADs a 
high priority for food security and surveillance.  
Also included for analysis in this study are two viruses indigenous to North 
America; porcine circovirus type 2 (PCV 2) and PRRSV. Members of the Circoviridae 
and Arteriviridae families, respectively, they are responsible for most of the production 
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losses to the North American swine industry (Nicholson et al. 2011; Zimmerman et al. 
2012, 405, 461 repectivly). Due to the etiology of these pathogens, the industry controls 
these viruses through rigorous sanitation and quarantine methods. These two pathogens 
are the causative agents for reproductive failure (Liu et al. 2013), lesions (Zimmerman et 
al. 2012, PCV2 410, PRRSV 470) and other clinical signs.  
Tests such as enzyme-linked immunosorbent assays (ELISA), virus isolation (VI) 
and virus neutralisation are regarded as the gold standard tests for most of the above 
target viruses (Table 2.1) (OIE - World Organization for Animal Health 2018, chaps. 
2.1.8, 2.8.1, 2.8.3, 2.8.6, 2.8.8,). Virus isolation typically requires at least 4-6 days to 
allow the virus to grow in cell cultures (Yamazaki et al. 2013). Recent advances in 
molecular biology have shown the use of reverse transcription polymerase chain reaction 
(RT-PCR) as a viable alternative for rapid and accurate detection of the viral targets. 
Single-plex RT-PCR assays use a single set of primers that target a specific genomic 
region of a particular virus or a group of genetically similar viruses. The power of a 
single-plex RT-PCR is the ability to detect low quantities of target RNA in a sample, as 
well as its ability to be specific to a particular genetic target (Desingu et al. 2015; S. M. 
Reid et al. 1999, 2000). Assays such as these have been used for detection and serotyping 
of FMDV (M. K. Baxi et al. 2006) and CSFV (Paton et al. 2000). One-pathogen/one-test 
can be a very efficient system when dealing with a single viral infection; however, in 
cases where multiple pathogens are suspected, the one-pathogen/one-test method requires 
the use of multiple tests being run against a single sample (Jiang et al. 2011; Hidalgo 
Ashrafi, Yee, and Paul 2009; Giammarioli et al. 2008). The increased number of tests 
needed for each sample increases sample, reagent and labour cost and time. An assay that 
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can simultaneously detect multiple genetic targets in a single reaction can improve the 
efficiency of diagnostic testing.    
Multiplexing refers to the amalgamation of multiple sets of PCR primers for 
different pathogens into a single assay (Belák 2007; Liu et al. 2013; Lung et al. 2011). 
Multiplexing has the potential to enhance diagnostic testing by reducing costs and labour. 
In cases of co-infection involving multiple pathogens, a multiplex PCR test has the 
potential to simultaneously amplify and differentiate possible targets (Diaz de Arce et al. 
2009; Ogawa et al. 2009; Lung et al. 2011, 2016, 2017). 
Microarrays are detection platforms that utilize sequence specific “capture” 
probes that hybridize with single stranded complimentary DNA “target” amplicons 
(Miller and Tang 2009) and are visualized using either colormetric (Fici et al. 2010; 
Spizz et al. 2015) or fluorescent (Takahashi et al. 2008; Lung et al. 2012) reporters. 
Microarrays have the ability to interrogate the sample with a large number of capture 
probes simultaneously, allowing for a great degree of multiplexing potential. Originally, 
microarrays were used for gene expression experiments utilizing a large number of 
probes to detect the expression of hundreds of genes simultaneously in systems including 
porcine (Gao et al. 2012) and bovine (Wilson et al. 2005). While most microarrays use 
passive hybridization, amplicons diffusing passively through a medium towards the fixed 
probes; electronic microarrays use electrical currents to actively pull negatively charged 
amplicons towards the probes. The use of the electrophoretic migration greatly reduces 
the time needed for hybridization (Syrzycka et al. 2003) and allows for rapid generation 
of results. The NanoChip 400 (Nexogen Inc., San Diego, US) takes this a step further by 
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using 400 individual test sites that can each be independently activated and tested 
separately. This allows for a greater degree of flexibility in assay design and execution.  
This study covers the development, optimization and validation of a seven-plex 
RT-PCR and electronic DNA microarray for the detection of five viruses exotic to 
Canada and two differential indigenous viruses that affect swine. The goal of this study is 
to develop an user-friendly assay that simplifies the diagnostic work flow for multi-
pathogen detection, reducing both time and cost for diagnostic tests and decrease 
response times to outbreak situations. 
 
2.2.0. Methods and Materials:  
2.2.1.0. Samples 
 
Seven high consequence viruses were selected for this study (Table 2.2). A panel 
of eight viral strains was used for initial testing of the seven-plex assay: FMDV SAT 3 
BEC 1/65, SVDV ITL 19/99, CSFV Alfort187, ASFV Lisbon 61, VESV Cal, PCV2 B, 
PRRSV YNL and PRRSV LV. Two lineages of PRRSV, North American (NA) and 
European (EU), were included to validate the ability of the assay to subtype and 
differentiate the two virus lineages. Initial development was done with 1/50 dilutions of 
the neat extracted virus total nucleic acid material. Due to the biocontainment 
requirements for experimental infections and the exotic viruses, all work involving 
unextracted viruses were completed in the biosafety level 3 laboratory (BSL3) at the 
Canadian Food Inspection Agency (CFIA) National Centre for Foreign Animal Disease 
(NCFAD) in Winnipeg Manitoba.  
 
30 
Synthetic constructs of FMDV were made for the 981 base pair (bp) region 
encoding VP3/VP1/2A/2B portions of the polyprotein and used as a surrogate of viral 
RNA during assay development in Lethbridge due to CFIA policy that FMDV viral RNA 
can only be used in the Winnipeg BSL 3 laboratories. RNA transcribed in vitro from 
plasmids containing synthesized DNA of FMDV, SVDV, CSFV, VESV and PRRSV, as 
well as plasmids, containing sequences of the two DNA viruses PCV 2 and ASFV, were 
used to determine the analytical sensitivity of the assay. RNA in vitro transcribed from 
amplicons of FMDV sequences was also used for development of the multiplex assay.  
Clinical material for 17 strains of four target viruses; FMDV, SVDV, CSFV and 
ASFV was obtained from experimentally inoculated pigs infected at the CFIA NCFAD 
laboratory. A number of oral and nasal swabs, whole blood and serum samples were 
collected and a final panel of samples were selected for testing (n=114). A total of 100 
oral and nasal swabs taken from <2 day old piglets (n=15) and >2 day old hogs (n=10), 
were obtained from Prairie Swine Centre, Saskatoon, Saskatchewan to be used as 
negative clinical material for specificity testing and virus spiking.     
 
2.2.1.1. Cloning and in vitro-Transcription of Target Viruses 
 
The target genes of SVDV, VESV, ASFV, PCV2 and PRRSV (Table 2.2) were 
amplified by RT-PCR reaction using Invitrogen’s SuperScript® III OneStep RT-PCR 
with Platinum® Taq kit (Life Technologies - Invitrogen, Burlington, ON). A 50 µL PCR 
reaction was made using the following reagents: 0.5-1 µL of the specific primers (50µM) 
for each individual target, 25 µL of 2x RT buffer mix, 2 µL of SSIII enzyme mix, 20-21 
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µL of ultra-pure water and 1 µL of target sample. The reactions were run on the Veriti 96 
well thermal cycler (Life Technologies-Applied Biosystems, Burlington, ON) at the 
following conditions: 55 °C RT for 15 min then 94 °C initial denaturation for 2 min, 
followed by 35 cycles of: 94 °C denaturation for 30 s, 50 °C annealing for 1 min and 68 
°C extension for 1 min and a final 68 °C extension for 5 min. All post-amplification RT-
PCR amplicons were visualized on the QIAxcel instrument (Qiagen, Toronto, ON). 
Amplicons were desalted and purified using the ZYMO DNA Clean & Concentrator™-5 
column kit (Zymo Research Corp., Irvine, CA, USA) and quantified on the NanoDrop 
8000 UV-Vis Spectrophotometer (ThermoScientific-NanoDrop, Wilmington, DE). 
Quantified amplicons for the five targets were treated with DNA blunting enzyme from 
the CloneJET PCR cloning kit (ThermoScientific-Fermentas, Ottawa, ON) for 5 min at 
22 °C. The amplicons were ligated to 1 µL of pJET1.2 (50 ng/µL) vector 
(ThermoScientific-Fermentas, Ottawa, ON) in a 3:1 insert:vector ratio, with 1 µL T4 
ligase (1U), at room temperature for 30 min.  
Ligated material was transformed into chemically competent “One Shot® MAX 
Efficiency® DH5α™-T1R” Escherichia coli (E.coli) cells. On ice, 3 µL of ligated 
material was incubated with 20 µL of cells for 30 min. The reaction was then heat 
shocked at 42 °C for 30 s, cooled on ice and inoculated with 250 µL of prewarmed 37 °C 
SOC media, and stored for 1 hour at 37 °C. 100 µL of cells were then plated on a LB 
Miller agar plate containing 100 µg/µL Ampicillin (100 mg/mL) and incubated at 37 °C 
overnight. Colonies were counted and a colony PCR was performed using 0.3 µL Taq 
polymerase (MP Biomedicals, Santa Ana, CA), 2 µL 10x Taq buffer, 0.4 µL 
deoxynucleotide triphosphate (dNTP, 10mM), and 0.4 µL of each of the pJET1.2 forward 
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and reverse primers. PCR reactions were run at 95°C for 3 min followed by 30 cycles of: 
93 °C for 30 s, 55 °C for 30 s and 72 °C for 1 min with a final extension step for 10 min 
at 72 °C. Five mL of overnight liquid cultures of selected colonies were set up in LB 
broth containing 5 µL of 100 µg/µL Ampicillin and incubated at 37 °C overnight. One 
mL glycerol stocks were made at 1:1 ratios with 60 % glycerol and stored at -80 °C. The 
remaining culture was pelleted at 14000 rpm for 3 min. The concentrated cells were 
extracted using the Qiagen QIAprep miniprep plasmid extraction kit (Qiagen, Toronto, 
ON) and the resulting pDNA was quantified on the NanoDrop 8000. 
A Zero Blunt® TOPO® PCR cloning kit was used (Life Technologies - Invitrogen, 
Burlington, ON) to clone the CSFV E1/E2 gene. Briefly,  the E1/E2 gene of CSFV was 
amplified with Platinum® Taq DNA polymerase High Fidelity (Life Technologies - 
Invitrogen, Burlington, ON) in a 50 µL PCR reaction with the following reagents: 1 µL 
of the CSFV primers (50 µM, Table 2.3), 5 µL of 10x high fidelity buffer, 1 µL of dNTPs 
(10 mM), 50mM MgSO4, 0.2 µL of Platinum® Taq polymerase (5 U/µL), up to 50 µL of 
ultra-pure water and 1µL of template RNA. The reactions were run on the Veriti 
thermocycler at the following conditions: 94 °C for 2 min, followed by 35 cycles of: 94 
°C for 30 s, 50 °C for 1 min and 68 °C for 1 min and followed by a final extension of 68 
°C for 5 min. After analysis on QIAxcel, the products were purified and ligated in a 
TOPO® blunt ligation reaction with 0.25 µL salt solution, 0.38 µL blunt amplicon, 0.25 
pCR™II-blunt-TOPO® vector and up to 1.5 µL H2O. The reaction was incubated for 30 
min at room temperature (~22 °C) and then chemically transformed into TOP10 
chemically competent E.coli cells following the same procedure as the pJET1.2 
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transformation with the exception that transformants were plated on LB agar plates and 
then grown in broth containing 100 µg/mL Kanamycin. 
FMDV synthetic constructs, containing the desired genomic regions, were 
synthesized by Integrated DNA Technologies (IDT) in the pGEM-3Zf(+) vector. FMDV 
plasmids were transformed into DH10B E.coli electro-competent cells. Briefly, 1 µL of 
plasmid was added to 20 µL electro-competent cells and incubated on ice for 5 min. The 
21 µL mixture is then added to a 1mm cuvette and electroporated in the BioRad Gene 
Pulser XcellTM electroporator unit (Bio Rad, Mississauga, ON) at: 1800 volts, 25 
capacitance and 200 resistance. After electroporation, 500µL of prewarmed SOC media 
is added and the cells were incubated at 37 °C for 1 hr. After incubation, the culture was 
plated as described above for CSFV.  
Quantified plasmid for SVDV, CSFV, VESV and PRRSV were restriction 
digested in a 250 µL reaction consisting of approximately 5µg plasmid DNA, 25 µL 10 
Rx buffer, 5 µL HindIII (10u/µL) (Thermo Scientific-Fermentas, Ottawa, ON), and up to 
250 µL dH2O. Plasmids in a volume of 25 µL were also run in a undigested control 
without the restriction enzyme and with 1/10 the volume of the template used in reactions 
with enzyme. Reactions were incubated at 37 °C for 16 hours. Digests were confirmed by 
running a 1 % UltraPure™ Agarose (Life Technologies-Invitrogen, Burlington, ON) gel 
at 100 volts for 45 min. The plasmid for FMDV was digested similarly but with 10 µL 
EcoRI enzyme (10U/µL) and 50 µL 10x Tango buffer (Life Technologies- Thermo 
Scientific-Fermentas, Ottawa, ON). Digestions were terminated by adding 12.5 µL 0.5M 
EDTA, 25 µL 3M sodium acetate and 500 µL ethanol (EtOH) to the reaction, incubated 
at -20 °C for 20 min and then centrifuged at 14000 rpm for 15 min at 4 °C. The 
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supernatant was decanted and the pellet was resuspended with 10 µL 1x TE buffer pH 8 
(Integrated DNA Technologies, Coraville, Iowa). The resuspended material was then 
treated with 1 µL of 2 µg/mL protease K and 0.5 µL 10 % Sodium Dodecyl Sulfate 
(SDS) and incubated at 50 °C for 30 min. Following treatment, material was purified 
using the Zymo column kit and eluted with 0.1xTE pH 8.0 and then quantified by 
NanoDrop.  
For RNA in vitro transcription, the MEGAscript® kit (Life Technologies – 
Invitrogen, Burlington, ON) was used for all RNA viruses (SVDV, CSFV, VESV, 
PRRSV) except for FMDV. A reaction mix was made up for the in vitro transcription 
containing; 1 µg of plasmid, 2 µL of each 75 mM dNTP (ATP, GTP, CTP and UTP), 2 
µL of 10x reaction buffer, 2 µL enzyme mix and up to 7 µL nuclease-free water for a 
final volume of 20 µL. The in vitro transcription reaction was continued for 4 hours at 37 
°C. Template DNA was removed by digestion with 3 µL TURBO® DNase (2 U/µL, Life 
Technologies-Ambion, Burlington, ON) at 37 °C for 30 min. The transcribed RNA was 
purified using the RNeasy mini kit “RNA clean-up” protocol (Qiagen, Toronto, ON) and 
run as per manufacturer’s specifications. Complete DNA removal was confirmed by PCR 
amplification of the digested material using a RT-PCR reaction with and without the RT 
component. RNA quantification was done using the Qubit® 2.0 Fluorometer system and 
RNA broad range kit (Life Technologies-Invetrogen, Burlington, ON). Copy number 
analysis was done using the following equation: 
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐(𝑐𝑐𝑛𝑛) 𝑥𝑥 6.022𝑥𝑥1023/𝑚𝑚𝑐𝑐𝑚𝑚𝑐𝑐
𝑏𝑏𝑐𝑐𝑏𝑏𝑐𝑐 𝑝𝑝𝑐𝑐𝑐𝑐𝑐𝑐(𝑏𝑏𝑝𝑝)𝑥𝑥 1𝑥𝑥109 𝑐𝑐𝑛𝑛 𝑛𝑛�  𝑥𝑥 𝑀𝑀𝑐𝑐𝑚𝑚𝑐𝑐𝑐𝑐𝑀𝑀𝑚𝑚𝑐𝑐𝑐𝑐 𝑊𝑊𝑐𝑐𝑐𝑐𝑛𝑛ℎ𝑐𝑐 𝑏𝑏𝑝𝑝 𝑛𝑛 𝑚𝑚𝑐𝑐𝑚𝑚𝑐𝑐�  
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In vitro transcribed FMDV RNA was done using PCR generated amplicons, 
rather than linearized plasmid. Template PCR amplicons for in vitro transcription were 
amplified in a 50 µL PCR reaction with the following reagents: 1.5 µL of M13 (-20) 
forward primer (5`-GTAAAACGACGGCCAG-3`, 50 µM) and M13 reverse primer (5`-
CAGGAAACAGCTATGAC-3`, 50 µM), 10µL of 5x Phusion HF buffer, 1µL of dNTPs 
(10mM), 0.5 µL of polymerase (5 U/µL) and up to 50 µL of ultra-pure water and 1 µL of 
template RNA. The PCR reactions were ran on the Veriti thermocycler at the following 
conditions: 94 °C for 2 min, followed by 35 cycles of: 94 °C for 30 s, 50 °C for 1 min, 68 
°C for 1 min and followed by a final extension of 68 °C for 5 min. 
 
2.2.2. Primer and Probe Design 
 
Literature searches were conducted initially to determine published genomic 
regions, primers and probes that have been used for detection of the target viruses. 
Genomic regions listed in Table 2.2 were selected because of a high degree of sequence 
conservation between known target sequences. Sequence databases were created from 
publically available sources such as the National Center for Biotechnology information 
(NCBI). Sequences were analyzed using an established bioinformatics pipeline routinely 
used by the lab. The pipeline includes sequence alignments with ClustalW (Larkin et al. 
2007) and management of sequences (such as trimming and deletion of sequences) using 
Bioedit (Hall, 1999) and Excel. Sequence databases for FMDV, CSFV, ASFV, PCV2 and 
PRRSV were generated to produce primers and probes as well as accurately screen 
existing primers and probes against known sequences. Briefly, databases of 
approximately 2880 FMDV sequences, 800 CSFV sequences, 171 ASFV sequences, 538 
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PCV2 sequences and 658 PRRSV full and partial sequences were generated. Sequences 
were then analyzed, to generate other possible primers and probes under in situ 
conditions using a primer/probe design software such as AlleleID® v. 7.7 (Premier 
BioSoft Internation, Palo Alto, CA). Resulting oligomers were analyzed by “Basic local 
alignment search tool (BLAST)” to identify candidate oligonucleotide primers and 
probes. Candidate primers and probes were selected based on how well the sequences 
aligned to its specific target and whether it matches any non-specific sequences. Primers 
and probes for SVDV and VESV were selected from the literature based on previous 
work (Lung et al. 2011). A non-specific binding probe (NSBP), used as a negative 
control and to establish baselines for non-specific reactivity on the microarray, was also 
obtained from the literature (Hindson et al. 2008). All oligonucleotides were ordered 
from IDT at 25 nM scale for testing and resuspended in 1 x TE. Working Stocks of 50 
µM and 10 µM were created for all primers and probes respectively, and stored at -20 °C 
until use.  
 
2.2.3.0. RT-PCR Optimization 
 
A panel of 16 primers was assembled from the literature search or designed after 
bioinformatics analysis. A seven-plex multiplex with an internal control was developed 
using the SuperScript® III OneStep RT-PCR with Platinum Taq kit. Using manufacturers 
suggestions; a 50 µL PCR reaction was made using the following reagents: 1 µL of the 
16 specific primers (10 µM) for each individual target, 25 µL of 2x RT buffer mix, 2 µL 
of SSIII enzyme mix, 20-21 µL of ultra-pure water and 1 µL of target sample. Initial RT-
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PCR conditions, run on the Veriti thermocycler, included: one cycle of 50 °C reverse 
transcription for 30 min and 94°C for 2 min followed by 40 cycles of 1 min of 94 °C, 1 
min of 50 °C and 1.5 min of 68 °C, followed by one cycle of a final extension of 68°C for 
5 min. Agarose gels made to 1% using UltraPure™ Agarose in UltraPure™ 10x TAE 
buffer (Thermo Scientific-Fermentas, Ottawa, ON) and mixed with 0.5ng/µL ethidium 
bromide (Sigma-Aldrich, St. Louis, MO), were used for visualization on the Gel Doc™ 
system (Bio-Rad, Mississauga, ON). 
Primer concentrations were altered one at a time from a final concentration of 0.2 
to 1 µM. Favorable concentrations of each primer, that best amplified of the target with 
the least negative effect on other target amplifications, were selected for further 
optimizations. After primer screening, RT-PCR running conditions were altered and 
compared. PCR running conditions tested include: RT temperature (50, 55 & 60 °C), RT 
time (15 & 30 min), denaturation time (2, 5, 7 & 10 min), annealing temperature (40, 45, 
48 & 50 °C), annealing time (30 & 60 s) and cycling number (35 & 40).   
To reduce non-specific amplification events, modified primers, dNTPs and master 
mix from TriLink Biotechnologies Inc. (San Diego, CA) were selected for testing. 
CleanAmp™ Precision primers and dNTPs are modified using a phosphotriester (PTE) 
group which work to hinder amplification until a high temperature is reached (Lebedev et 
al. 2008; Hidalgo Ashrafi, Yee, and Paul 2009). A 3`PTE group is added to each forward 
primer of the seven targets and then amplified in single-plex and in multiplex at standard 
concentrations. Amplicons were run on 1% agarose gels. The CleanAmp™ dNTPs were 
tested at standard concentration (0.2 mM final) and run using a 10x PCR buffer, supplied 
by TriLink, and the SSIII polymerase. TriLink supplied reagents to test their 
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CleanAmp™ One-Step RT-PCR 2x Master mix. The CleanAmp™ master mix was tested 
along side the standard assay using the same running conditions, with the exception of a 
72 °C extension temperature.  
 
2.2.3.1. Microarray Optimization 
 
The microarray assay optimization was split into two components: Pre-treatment 
and Post-treatment. Pre-treatment conditions included addition of 1% sodium hydroxide 
(NaOH) and Lambda exonuclease (Thermo Scientific-Fermentas, Ottawa, ON) to keep 
the DNA in single strand form longer and to digest the anti-sense strand respectively. 
Post-treatment conditions included; reporter choice, reverse biasing and addressing time 
and amperage. All conditions were tested with and without the post treatment and run as 
per standard settings. 
To optimize pre-treatment conditions, a solution of 1% NaOH was added to the 
PCR amplicon before addition to the plate. Samples were then heated at 95 °C for 5 min 
and then snap cooled on ice before addition to the plate. Testing of Lambda exonuclease 
required the PCR amplicons to be generated with 5`phosphorylated forward primers. A 
25 µL reaction mixture of: 2.5 µL 10x Reaction buffer, 1 µL Lambda exonuclease and 
21.5 µL of amplicon DNA, was set to incubate at 37 °C for 30 min and then heat 
inactivated at 75 °C for 15 min. 
Optimization of the post-treatment conditions included the following; two 
reporter probes were tested for the detection of foot-and-mouth disease virus (FMDV), a 
Red Universal reporter (RUR) and a 5` Red Specific reporter (5RS). The 5RS is a 
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reporter that is specific to a region in the FMDV amplicon and will only react to FMDV, 
while the RUR is sequence specific to the tag sequence that is added to all of the reverse 
primers when amplifying the target pathogens. Each reporter probe was added separately, 
together, or one after the other to the plate before the run. Addressing times were altered 
from 120, 60 and 30 s, and addressing temperatures were also modified from 995, 800, 
600 and 400 nA. Each time change was tested using each temperature setting until an 
optimal positive signal to negative background was reached. Reverse biasing (RB) is the 
use of a reverse current that will theoretically drive away any unbound targe DNA or 
reporter. The RB was tested using time intervals; 30, 10, 5, 2, 1 second and amperages 
from -995, -350, -150, -50 nA, at the end of the reporting stage of the microarray. 
 
2.2.3.2. Seven-plex Multiplex RT-PCR  
 
A multiplex RT-PCR was developed to amplify seven viruses that affect swine. 
The seven-plex RT-PCR with 22 primers (Table 2.3) was developed using SSIII OneStep 
RT-PCR with Platinum Taq kit. Each 50µL RT-PCR reaction consisted of the following 
reagents: 1 µL each of 1µM FMDV, CSFV and PCV2 primers (n=6) and 0.5µL each of 
0.5 µM SVDV, VESV, ASFV and PRRSV primers (n=8), 25 µL of 2x RT buffer mix, 2 
µL of SSIII enzyme mix, 15 µL of ultra-pure water and 1 µL of template. The RT-PCR 
reactions were performed with the Veriti thermal cycler using the following conditions: 
55 °C RT for 15 min, then 94 °C for 2 min for initial denaturation, followed by 35 cycles 
of 94 °C for 30 min, 50 °C for 1 min and 68 °C for 1 min, followed by a 5 min final 
extension step at 68 °C.  
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Post-amplification reactions were visualized using one of two methods: The 
QIAxcel system was used for most samples, except for FMDV samples and clinical 
samples that were done on standard gel electrophoresis with SYBR® Safe (Life 
Technologies-Molecular Probes, Burlington, ON) in Winnipeg. The QIAxcel is an 
automated gel electrophoresis system that utilizes a multicapillary cartridge with agarose 
gel and small amounts of Ethidium Bromide (EtBr) to visualize the DNA. Briefly, post-
PCR samples are loaded into a 12 slot tray, after which the machine is run using the 
AM320 settings. The cartridge draws up <0.1µL of sample and runs it through the gel 
contained within the cartridge, where a detector measures the excitation of the EtBr 
bound to the DNA by a LED light. Then a photomultiplier collects the data and the 
BioCalculator software calculates and creates the gel image. Mixtures of two size 
markers (15 and 3000 base pairs) are used in every run as a size reference. For 
conventional agarose gel electrophoresis, a 1% agarose gel is made with 1xTBE buffer, 
UltraPure™ Agarose and 2µL of SYBR® Safe. 5µL of amplicons are added to 1.5µL 
loading dye, loaded onto the gel and ran at 100 volts for 45 min and visualized using a 
Gel Dock system (Bio Rad, Mississauga, ON). 
To determine the analytical sensitivity and to examine effects on amplification 
sensitivity, the RT-PCR assay was tested using three methods; single-plex with primers 
for single virus, seven-plex multiplex with all 22 primers, a five-plex with primers for the 
five exotic viruses (FMDV, SVDV, CSFV, ASFV, VESV), and a duplex assay for the 
two indigenous viruses (PCV2, PRRSV). All cycling conditions for each method are 
similar to seven-plex assay. PCR buffer compositions are also similar except for the 
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removal of appropriate primers (i.e. a single primer pair was used in the single-plex assay 
and five pairs of primers were used in the five-plex assay). 
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2.2.3.3. Electronic Microarray 
 
The NanoChip 400 electronic microarray is an “Amplicon-to-Answer” system 
that automates and integrates all steps in microarray processing such as; probe printing, 
electrophoretically-driven hybridization, washing and reporting using one automated 
machine and disposable cartridges with 400 features. The NanoChip 400 platform 
consists of a small cartridge that contains an array of 400 test sites that are independently 
controlled by platinum electrodes covered in streptavidin containing polyacrylamide 
hydrogel (Papatheodorou et al. 2010). The protocol and methods for the NanoChip 400 
assays were described previously (Lung et al. 2012; Papatheodorou et al. 2010). Briefly, 
a 96-well plate is set up to contain; 250 nM of each sequence specific biotin-labeled 
capture probes (Table 2.4) diluted in buffer mixture consisting of 50 mM Histidine 
(Sigma-Aldrich, St. Louis, MO) and 0.05% proclin® 300 (Sigma-Aldrich-Supelco, 
Bellefonte, PA), otherwise called “Hisproclin”. A mixture of 8.75 µL post RT-PCR 
amplicons and 61.25 µL Cap-down A buffer (Nexogen, Inc., San Diego, CA) were added 
to the plate, as well as 2.8 µL of 1 µM fluorescent universal reporter probe in 67.2 µL 
High Salt Buffer (Nexogen, Inc., San Diego, CA). Samples were run in duplicate with a 
No Template Control (NTC) on each cartridge. A panel of virus-specific capture probes 
printed on the array includes at least two probes per target as well as the NSBP probe as a 
negative control to determine baseline non-specific reactivity.  
At the start of the program, the NanoChip 400 instrument prints the capture 
probes to specific user-designated electrode-controlled test sites on the platinum array, 
using user defined parameters (350 nA of current for 30 s for this study). The array is 
then washed with a mixture of Hisproclin and 20% Triton X100 (Sigma-Aldrich, St. 
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Louis, MO) and then with milliQ water plus 0.05% proclin® solution five times. The 
target amplicons are then addressed to designated test sites for 60 s at 800 nA and then 
washed with Hisproclin/Triton mix and water. The universal reporter probe was added to 
the array at 60 °C, the temperature was lowered to 55°C for 60s and further reduced at 2 
°C increments every 20 s until 25 °C. At this point High Salt Buffer (HSB) wash was 
applied and an image was taken at 24°C followed by another HSB wash and a final wash 
at 50°C. Three additional imaging steps were carried out at the end at different 
integration times; 1500, 1250 and 1000ms to allow selection of the image with optimal 
signal to noise ratio, if needed. Fluorescence data generated by the hybridization of the 
reporter probe to the bound target from the 1250ms images were used to calculate the 
Positive:Negative (PN) ratios.  The PN ratios were calculated by dividing the specific 
target signal by the background signal generated by the NTC, which is run with each 
cartridge.  An experimentally determined cut off of a PN ratio of two was used to 
determine whether a sample is positive or negative. 
 
2.2.3.4. Initial Assay Validation 
 
 An initial panel of 58 laboratory amplified strains representing the diversity of 
the target viruses, including all known serotypes of FMDV (n=7) and genotypes of CSFV 
(n=3) were selected to validate the amplification and detection of the selected primers, 
probes and methods used in the developed assay. A collection of 11 oral and nasal 
clinical swab material from healthy hogs, as well as 11 non-target virus and bacteria that 
affect swine, were also tested to evaluate assay specificity, for a total of 22 negative 
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samples (Table 5). Overall, a total panel of 80 samples were used in the validation of the 
seven-plex assay. 
The RT-PCR followed the above stated multiplex protocol (2.3.0.) and all 
samples were amplified within a 24 hour period to reduce variability from RNA 
degradation. The 22 negative samples were run twice; with and without a 1/50 dilution of 
PRRSV YNL RNA spiked in as a control to rule out the presence of inhibitors. All 
samples were run on QIAxcel for visualization. The standard NanoChip 400 microarray 
protocol was used for detection, followed by analysis.  
 
2.2.4.0. Clinical Samples 
2.2.4.1. Evaluation of Clinical Samples 
 
From a list of over 1000 clinical samples, collected from the experimentally 
inoculated pigs, a panel of 114 samples were chosen for use in this study. The clinical 
samples for FMDV and SVDV were extracted using QIAamp viral RNA kit (Qiagen, 
Toronto, ON) and RNeasy mini kit (Qiagen, Toronto, ON) for CSFV and ASFV, as per 
manufacturer’s specifications. The samples were evaluated first by using the animal care 
reports supplied by the animal care veterinarians to see when first signs of infection 
appeared, secondly by the seven-plex RT-PCR and thirdly by real time PCR for 
quantification. Amplicons generated were visualized using agarose gel and SYBR safe. 
NanoChip 400 conditions used for testing clinical samples are described below.  
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2.2.4.2. Experimental Inoculation (Spiking) into Clinical Material 
 
Clinical samples containing VESV, PCV2 and PRRSV were not available for this 
study, thus lab amplified viruses were spiked into biological material from healthy animal 
to simulate clinical samples. Biological material used for spiking included oral and nasal 
material (Prairie Swine Centre, Saskatoon, SK). For PCV2 and PRRSV, 14 µL of 
laboratory-propagated virus (1.4x1010 and 5.2x109 TCID50/mL, respectively) was spiked 
into 126 µL of biological material and was extracted with the RNEasy mini kit (Qiagen, 
Toronto, ON). For VESV, 20 µL of virus culture was spiked into 120 µL of clinical 
material and extracted with the QIAamp viral RNA kit. All extracted spiked samples 
were tested for the presence of target viruses with the seven-plex assay.  
All post-PCR amplicons for inoculum and spiking were run on the NanoChip 400 
using the optimized protocol. A total of six samples and a NTC (N=7) were run on each 
cartridge, in duplicate, against the full panel of specific and negative capture probes 
(n=28). Repeats were determined by selecting samples with unexpected or discordant 
results. For repeats, the amount of starting template material used was increased from 1 
µL to 3 µL for samples that amplified, failed to amplify, and samples with low 
microarray signal were repeated by increasing the amount of amplicon added to the array 
from 8.75 µL to 16 µL.  
 
2.2.5. Limit of Detection: Analytical Sensitivity 
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In vitro transcribed RNA was used to determine the analytical sensitivity of the 
assay for each target. After quantification, in vitro transcribed RNA was diluted serially 
from neat stock to 10-12 in dH2O. The serial dilution mixture consisted of 18 µL dH2O 
and 2µL neat RNA sample (FMDV=1.9x1012, SVDV=1.2x1012, CSFV=3.5x1011, 
VESV=6.4x1011, ASFV=1.4x1010, PCV 2=3.9x1010 and PRRSV=1.1x1012 copy 
number/µL) for a 10-fold dilution and the process was repeated 11 more times to create 
the full dilution series. The dilutions were all made on the same day they were used. To 
amplify, 1 µL of the dilution series was amplified using the standard seven-plex 
multiplex, five-plex exotic, two-plex indigenous and single-plex RT-PCRs and imaged 
using the QIAxcel. RT-PCR end points were determined by the last reaction in the series 
to give a visually detectable band. To determine the last detectable band, an arbitrary 
threshold cut-off set by the QIAxcel program on the electropherograph was used; 
presence of a band of the expected size with signal intensity above the threshold were 
categorized as positive, while an intensity below the threshold was considered negative.  
A panel of six samples from each dilution series including; two samples above the 
RT-PCR endpoint and three samples past the endpoint, were chosen to run on the 
NanoChip 400 assay with a positive control and NTC (n=8) in duplicate on each 
cartridge. The eight samples were run against a reduced panel of detection probes that 
included only the specific target probes (ie. FMDV samples tested against the five FMDV 
probes) as well as the NSBP as a negative control probe. The optimized NanoChip 400 
assay was used throughout the experiment. The PN ratio cutoff for positivity of 2 was 
used to determine the analytical sensitivity of the microarray assay. PN ratios ≥1.7 and ≤ 
2 were designated as suspect.  
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2.3.0. Results 
2.3.1.1. Multiplex RT-PCR development 
 
A multiplex RT-PCR assay was developed to target seven high consequence 
viruses that affect swine. A final set of 22 primers was selected to amplify the seven 
viruses (Table 2.3). Primers were chosen because of their selective reactivity to the target 
virus as seen in Figure 2.1. The seven-plex RT-PCR amplified the target viruses, 
including all 7 serotypes of FMDV, 3 genotypes of CSFV, both genotypes 1 (EU) and 2 
(NA) of PRRSV. All targets generated amplicons of the expected size. Oral material from 
healthy animals and No-Template Control (NTC) did not produce any amplification 
product (Figure 2.1).   
 
2.3.1.1.1. Seven-plex RT-PCR Multiplex Optimization 
 
Optimization of the primer concentrations showed that the FMDV and CSFV 
amplified its targets best at 1 µM primer concentration while the other primers amplified 
most specifically at 0.5 µM. After determination of primer concentrations, cycling 
conditions such as; RT time and temperature, initial denaturation time, annealing time 
and temperature, and cycling number were tested. Results showed that increasing the 
denaturation and RT time had little effect on amplification while increasing the RT 
temperature to 55 °C did increase the specificity of amplification for FMDV (data not 
shown). 
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Modified primers from Trilink were evaluated to determine whether it could 
increase the specificity of the seven-plex RT-PCR. In single-plex, the modified primers 
showed lower band intensities than the non-modified primers for FMDV, CSFV, VESV 
and PRRSV. No amplification was seen for ASFV and PCV 2 with the CleanAmp 
primers, while SVDV was the only sample to show higher intensities than control 
unmodified primers (Figure 2.2). No bands were detected when the full set of 
CleanAmp™ primers were used for the seven-plex RT-PCR with or without using the 
CleanAmp™ dNTPs (data not shown).  
 
2.3.1.1.2. Seven-plex RT-PCR Validation 
 
A panel of 58 viral samples of the seven target viruses (Table 2.5) were amplified 
with the optimized seven-plex RT-PCR. Panels of the target viruses were selected from 
available laboratory strains that represent the diversity of strains and included all seven 
FMDV serotypes and 3 genotypes of CSFV. A full FMDV panel of 23 strains were 
amplified successfully along with 12 SVDV, 10 CSFV, one VESV, three ASFV, one 
PCV 2 and eight PRRSV strains.  
The FMDV samples showed non-specific amplification that was weaker than the 
specific FMDV amplicons (Figure 2.3A). All 35 non-FMDV isolates of target viruses 
amplified well, with minimal non-specific bands (Figure 2.3B). 
A total of 11 oral and nasal swabs from healthy pigs as well as 11 non-target 
swine bacteria and viruses were used to assess the specificity of the amplification. 
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Twenty one of the 22 samples used to test specificity did not result in detection of 
amplified products unless the sample was spiked with 1 µL of 1/50 dilution of PRRSV 
YNL RNA as an exogenous control. With the Streptococcus suis sample, some non-
specific banding was observed possibly due to non-specific primer binding. The 
exogenous control, spiked PRRSV, was detected, indicating there is no detectable level 
of PCR inhibition (Figure 2.3C & 2.3D).  
 
2.3.1.2. NanoChip 400 Electronic Microarray 
2.3.1.2.1. NanoChip 400 Optimization 
 
RT-PCR amplicons were transferred to the NanoChip 400 electronic microarray 
for screening of the 46 capture probes designed for detection of the target viruses. The 
NanoChip 400 was optimized with the following conditions separately; addressing 
conditions, wash buffer, reporter probes and pre/post-treatment of amplicons. Amplicons 
were treated with either; 1% NaOH, heat denaturing, or lambda exonuclease prior to 
addition to NanoChip 400 array. NaOH and lambda exonuclease showed similar or lower 
fluorescence values than the non-treated controls (data not shown). Results for the 
addressing conditions showed that 800nA for 60 s was optimal and produced the highest 
fluorescent signals to background (data not shown). Testing of two different reporters 
probes showed that the 5RS reporter had higher fluorescent signals and lower 
backgrounds than the RUR reporter. RUR reporter generated PN ratios for positive 
signals about 2 PN levels lower than the 5RS reporter as well as showed higher 
background. All fluorescent signals were lost after all RB treatments, where the 
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electrodes were given a negative charge as compared to the regular positive charge, such 
as -995 nA for 30 s. The only exception was -50 nA for 1 second, which generated weak 
results comparied to the non-RB data (data not shown). 
Following optimization, 27 capture probes, at least two probes per target, were 
selected along with a negative control non-specific binding probe (Table 2.4). The panel 
of 28 probes, the seven virus amplicons and a NTC sample were addressed to the 
microarray using the optimized protocols. All targets reacted as expected with their 
respective capture probes whereas the probes for PRRSV EU and NSBP remain 
unreactive due to lack of specific targets to bind to (Figure 2.4). 
 
2.3.1.2.2. NanoChip 400 Electronic Microarray Validation 
 
The panel of 58 validation isolates and 22 negative control samples were tested in 
duplicate against the select panel of 27 capture probes and one negative binding probe 
using the optimized protocol. All probes gave good fluorescent sensitivity to their target 
virus without any cross reactivity to non-target samples. All negative control samples 
showed no cross reactivity (Figure 2.5).  
 
2.3.2. Testing with Clinical Samples 
 
A total of 126 clinical samples, collected from experimentally infected pigs, were 
chosen for extraction and evaluation using the seven-plex multiplex assay. Most of the 
samples tested all detected to comparable days post-infection (dpi) levels with both the 
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real time and seven-plex RT-PCR. However, FMDV RNA in serum samples were 
detected as early as dpi 1 whereas a real time RT-PCR used by the reference laboratory in 
Winnipeg first detected the virus at dpi 2. Targets were detected in a variety of sample 
types including; nasal, oral, serum and whole blood. First detection ranging from 1 dpi 
for SVDV, 4 dpi for ASFV and 5 dpi for CSFV (Table 2.6). For VESV, PCV 2 and 
PRRSV, virus culture was experimentally inoculated into oral and nasal samples were 
successfully detected (Table 2.6).  
 
2.3.3. Limit of Detection: Analytical Sensitivity 
 
Figure 2.6 depicts the amplification of SVDV ITL 19/99 transcribed RNA using 
the three different RT-PCR tests. The target was amplified out to the 1x10-8 dilution for 
single-plex and five-plex multiplex and 1x10-7 for the seven-plex RT-PCR. All other 
virus dilution series amplified well with the three RT-PCRs and detected using the 
NanoChip 400 (Table 2.7). The sensitivity of the assay was best for ASFV, PCV 2 and 
PRRSV at approximately 1 copy by PCR and 10 copies by microarray, followed by 
SVDV, CSFV and VESV at around 10 and 100 copies by PCR and microarray 
respectively. The lowest detection was observed for FMDV at around 100 copies by PCR 
and 1000 copies by microarray. In general, the single-plex and five-plex RT-PCRs, had a 
sensitivity that was 10 fold better than the seven-plex RT-PCR assay (Table 2.7). 
 
2.4.0. Discussion 
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The seven viruses chosen for this project represent a threat to the Canadian 
livestock industry, economy and ecosystem. With this in mind, the government of 
Canada has implemented procedures and validated tests to detect and protect against 
these pathogens as prescribed by the OIE ‘Manual of Diagnostic Tests and Vaccines for 
Terrestrial Animals’. The main problem facing the diagnosis of these different viruses are 
shared clinical signs such as; the vesicular lesions caused by SVDV and VESV being 
clinically indistinguishable from FMDV (Banér et al. 2007). The purpose of this project 
was to develop a user-friendly diagnostic assay with the ability to detect and differentiate 
between seven high consequence swine viruses in a single reaction using a multiplex RT-
PCR paired with an automated NanoChip 400 electronic microarray.  
Optimization of the assay stemmed from the complex interactions between the 
primers, amplicons and the probes. A Dengue virus internal control was removed from 
the assay due to its strong heterologous reaction with FMDV and PRRSV primers and 
once removed; stronger amplification of FMDV and PRRSV was observed (data not 
shown). Homologous primer interactions also pose a challenge to assay sensitivity by 
reducing the amount of available primers in the reaction (Yuryev 2007). Though the PCR 
and microarray assays were optimized for this project, further optimizations may improve 
the amplification, sensitivity and turn around time. Optimizations including more 
efficient enzymes, reaction buffers or chemical modifications have the potential to 
increase sensitivity of the assay. One optimization that was evaluated was the TriLink 
Biotechnologies’ CleanAmp™ primers and dNTPs. The CleanAmp™ system uses a 
chemical modification on the forward primer to block the DNA polymerase during the 
initial reverse transcription step to reduce possible mispriming (Shum and Paul 2009; 
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Hidalgo Ashrafi, Yee, and Paul 2009). Kits and modifications such as these have the 
potential to enhance amplification of single or multiple targets. The CleanAmp™ primers 
and dNTPs tested in this project only produced amplicons in single-plex reactions, but 
not in multiplex reactions (Fig 2.2). One explanation for why the multiplex PCR failed 
may be due to high DMSO in the buffer used to suspend the primers. DMSO is used to 
promote DNA separation in regions of high GC content (Jensen, Fukushima, and Davis 
2010). When the primers are diluted to at least 0.5 µM in H2O, the DMSO concentration 
is diluted 400x. This allowed the single-plex reaction to work, but in a multiplex reaction 
with seven modified primers, the concentration of DMSO is 36x the original 
concentration. Though the CleanAmp™ system didn’t work in a multiplex system, the 
primers may be useful by introducing the modified primers for problem samples that are 
highly reactive to non-specific oligonucleotide sequences.    
The developed RT-PCR amplified a panel of 58 viral strains, representing all 
seven high consequence viruses, with serotype and genotype representations for viruses 
such as FMDV (S. M. Reid et al. 2002) and CSFV (Dirk Deregt et al. 2006). The RT-
PCR did not show significant non-specific amplification of 11 clinical materials from 
healthy pigs and 11 non-target viruses and bacteria associated with livestock. Some weak 
non-specific amplifications representing mispriming of the 22 primers with the sample, 
are non-reactive against the capture probes in the microarray. Amplicon mispriming 
could potentially lower assay sensitivity by reducing amplification of specific targets, 
creating a competitive PCR (Peyrefitte et al. 2003). Mispriming can be reduced by 
incorporating in silico analysis and avoiding primers that bind to host or relevant non-
target sequences. 
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For optimizing the microarray assay, a 1% NaOH amplicon denaturing step was 
added prior to addition to the microarray. Since the microarray only requires the anti-
sense strand of the amplicon containing the reporter tag sequence to hybridize to the 
capture probe, it was hypothesized that this treatment would increase sensitivity, by 
increasing specific annealling of the target DNA and capture probes. The lack of affect 
maybe due to the low NaOH concentration. One explaination could be that the change in 
NaOH changed the electro competence of the solution, or the electrical currents potential 
to travel through a liquid medium. The Cap down A buffer (CdA) that is used to suspend 
the amplicons needs to be between 0 and 100 µS/cm to allow for correct current travel, 
and the addition of the NaOH changes the competence of the buffer (data not shown). A 
solution containing 1% NaOH was the maximum percentage that would result in a buffer 
with the required 0-100 µS/cm range. A lambda exonuclease step was evaluated to digest 
any DNA strand that has a 5` phosphate, leaving the tagged antisense strand for 
hybridization (Lung et al. 2015). Though a single stranded product was being produced, it 
is possible that it wasn’t enough to increase the efficiency of hybridization as compared 
to the no-treatment control. Another possibility is that the addition of the exonuclease 
reaction, buffer and exonuclease, was reducing hybridization efficiency.  
Reverse bias in theory can aid washing by electrophoretically driving any 
unbound amplicons away from the array surface and the probes by giving it a negative 
charge. Experimentally, it was observed that at most of the conditions tested, most or all 
signal is lost suggesting that the reverse current is too strong and prevented hybridization 
of the target amplicon with the capture probes or annealing of the fluorescent reporter 
with the tag sequence on the amplicon. At low amperages and times, a significant amount 
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of signal remained after RB, though it was not as high as the no-RB control (data not 
shown).  
Using clinical material, the RT-PCR and microarray assays detected viral nucleic 
acid as early as 1 dpi in serum from animals experimentally inoculated with FMDV, as 
well as in other sample types (ie, oral and nasal swabs, and whole blood). Detection from 
the samples varied widely depending on the status of the infection. One experimental 
infection of ASFV failed to show clinical signs until day 13 due to a late start to the 
infection seen when the animal failed to show symptoms until days after inoculation 
(animal care notes, data not shown). Due to the lack of clinical samples for VESV, PCV 
2 and PRRSV, these viruses were spiked into biological material collected from healthy 
≥2 day old hogs. Detection of viral nucleic acid in spiked samples showed that the assay 
is able to detect these viruses in biological material.  
The analytical sensitivity of the seven-plex, five-plex exotic and 2-plex 
indigenous RT-PCRs were determined using quantified in vitro transcribed RNA. The 
lowest limits of detection observed for the seven-plex RT-PCR were for PRRSV, PCV 2 
and ASFV. These three viruses have the smallest amplicons (379-537bp). Two of the 
viruses with small amplicon size are DNA viruses, which make the RT step during PCR 
irrelevant. The use of the RT step with the DNA viruses may make the amplification 
more efficient in comparison to the larger amplicons from the RNA viruses. This could 
be due to the fact that present in clinical samples, the DNA virus may have both DNA 
and messenger RNA strands present for amplification, while the RNA viruses will have 
just the messenger RNA and genomic RNA, but no initial DNA present, giving a possible 
detection advantage to the DNA viruses.  
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Due to the unavailability of virus stocks in Lethbridge, the in vitro transcribed 
RNA was used as a facsimile for the five RNA viruses present in the multiplex. Though 
the use of real virus stocks to determine the analytical sensitivity would have been 
preferable to only a small region of the whole virus genome, it is difficult to accurately 
quantify the virus samples propagated in vitro due to high levels of secondary structure 
(Plaskon, Adelman, and Myles 2009) or by random-priming of cellular or exogenous 
small nucleic acids (Timofeeva and Skrypina 2001) that are released during extraction. 
Using In vitro transcribed RNA is favourable also because it has a higher degree of 
reproducibility during quantification and testing (Schibler et al. 2012).  
The limit of detection (LOD) for FMDV was lower than the other targets. The 
most likely reason for this lower sensitivity is due to the size of the amplicon. The 
selected FMDV amplicon was 981bp long to allow simultaneous serotyping. The VP1 
capsid protein-coding region is a highly variable region making it ideal for subtyping 
FMDV (Carrillo et al. 2007). It has been documented that larger amplicons generated by 
PCR produce lower yields than shorter PCR products due to a few possible reasons. One 
reason for the lower yield could be 3`-terminal base mismatching in primer binding, 
causing early termination or hindering strand synthesis (Cheng et al. 1994). The location 
of the mismatch is important if the mismatched nucleotide is located within the last four 
nucleotides from the 3`-terminus, the reaction yield is either greatly reduced or fails to 
amplify. Similar reactions were seen by other researchers that saw reduced amplifications 
depending on what kind of mismatch was present (Huang, Arnheim, and Goodman 
1992). Another issue that may be affecting the LOD can be the competition between the 
FMDV and other primers in the assay. It was seen earlier in the project that the Dengue 
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virus internal control sequence, was forming primer dimers on multiple primers in the 
assay, FMDV and PRRSV being one (data not shown). After removing the Dengue 
primers from the assay, amplification for the affected targets increased. There may be a 
similar effect happening between the FMDV primers and another set of the primers in the 
assay. All work with the FMDV samples was done quickly and completed, from serial 
dilution and quantification to microarray within a two-day span. This helps reduce the 
variation that may occur due to freeze-thaw cycles, causing degradation of the RNA that 
would decrease amplification efficiency. Another possible cause could be the presence of 
PCR inhibitors that affect amplification of larger targets more than small ones. With the 
likely culprit of the low FMDV sensitivity being its amplicon size, future work on 
reducing the amplicon size by either reducing within the current genetic region finding 
another conserved region may facilitate a more efficient reaction.  
Electronic microarrays are a powerful tool for detection and typing of pathogens. 
The process of using an electrical current greatly increases the level of detection and the 
speed of hybridization by driving the negatively charged nucleic acid amplicons towards 
the probe bound test site in milliseconds compared to normal passive hybridization 
(Miller and Tang 2009) which relies on diffusion and can take hours to hybridize 
efficiently. Microarrays have been integrated into both human and veterinary medicine in 
the attempt to develop rapid and accurate point of care (POC) diagnostic tests. These 
POC tests are described as a near-patient test that is utilized in either a hospital setting for 
testing by medical personnel (S. Park et al. 2011; Niemz, Ferguson, and Boyle 2011) or 
pen side by a veterinarian (Bollo 2007). This gives the professional the greatest ability to 
rapidly diagnose diseases. Though a large benchtop system such as the NanoChip 400 is 
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less suitable for use as a POC machine, the technology used in the systems can be used in 
more mobile and cost effective instrumentation that can reduce both time and costs in 
POC lab-on-chip instruments (Tan et al. 2014; van Reenen et al. 2014) and Rheonix 
EncompassMDx workstation and disposable CARD® cartridges (Spizz et al. 2012). 
Diagnostic systems such as the one described here has potential to complement 
existing tests and contribute to the economic stability of Canada. Gold standard tests have 
all been used in the detection and diagnosis of FAD outbreaks from VI for FMDV, 
ELISA assays for CSFV, virus neutralization for SVDV, indirect fluorescent antibody 
test for ASFV or Real-time PCR for VESV, PCV 2 and PRRSV (Table 1). These tests are 
described on the OIE website: http://www.oie.int/. These methods have been selected due 
to their sensitivity of detection by having distinct tests and antibodies for the different 
serotypes (OIE - World Organisation for Animal Health 2012, 2:149). Examples  include 
the seven serotypes of FMDV and certain ELISA tests, such as the 3AB1 non-structural 
protein ELISA, have been shown to differentiate between infected samples and samples 
from vaccinated animals (Jaworski et al. 2011). 
 However, the problem with an ELISA test is that it requires high viral loads and 
specific sample types to accurately identify a true positive sample. If any sample is 
suspected of having too low of titres or the sample is an unusable type, such as milk or 
clotted blood, the sample must be sent for cell culturing which may take up to four days 
(S. Reid et al. 2003). Likewise other gold standard tests, such as VI and complement 
fixation, can hinder rapid diagnosis based on their nature. Virus isolation requires long 
incubation times of up to typically 4-6 days and complement fixation is complex and can 
introduce false biases into the results due to anti-complex formations (Ferris and Dawson 
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1988). Tests such as these require highly trained technicians and specialized equipment, 
leading to increased cost. These tests are also hindered by their low throughput, which in 
an outbreak situation where hundreds of samples need to be processed quickly, valuable 
time is spent on laboratory confirmation using single target tests. Laboratory 
confirmation of samples is important to confirm that the target pathogen is present or if 
there is any chance of another virus as the causative agent. An example of this can be 
from a possible FMDV outbreak where laboratory test must not only confirm the 
presence of FMDV but also rule out other viruses such as SVDV and VSV that cause 
similar clinical signs (Núñez et al. 1998; Lung et al. 2011; Fernández et al. 2008; Banér 
et al. 2007). The elapsed time in laboratory confirmation puts the surrounding areas and 
affected region in jeopardy of the spread of infection before any level of quarantine can 
be implemented.  
The NanoChip 400 takes many of these issues into account, from the sensitivity to 
the throughput. The use of the electronic currents both increases sensitivity of low 
template samples as well as reduces wait times. With the use of the 400 individually 
controlled test sites; as many as 400 samples can be tested against one probe on a single 
cartridge. With the inclusion of multiplex RT-PCR technology, the NanoChip 400 is able 
to accurately detect multiple targets from a single amplified sample. Though the system 
can aid in diagnostic testing, one drawback is the reliance on separate DNA/RNA 
extractions and RT-PCR amplification to generate the appropriate template to run in the 
instrument. The separate extractions and RT-PCR require trained technicians to complete 
as well as add processing time to the test; thereby, increasing the chance of contamination 
with any handling steps. With systems that offer a rapid diagnosis and high throughput, 
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quarantine of affected farms and geographical areas can be put in place faster, halting the 
possible spread of infection. The combination of multiplex RT-PCR assays and electronic 
microarray technology offers this rapid and sensitive diagnostic capability by reducing 
the number of different tests that need to be run and decreasing the time between sample 
submission and test results. Savyon Diagnostics (Ashdod, Israel) has developed a new 
NanoChip 400 system call the NanoChip 400 XL which incorporates a PCR component 
into the workflow of the machine, reducing the manual handling steps required 
(https://www.savyondiagnostics.com/). 
In conclusion, the “amplicon-to-answer” seven-plex RT-PCR and associated 
microarray assay was able to specifically amplify, detect and differentiate between seven 
high consequence swine viruses. Further testing is desirable to further optimize the RT-
PCR. This project will be used as a starting point for integration onto advanced “sample-
to-answer” systems to further increase the speed and automation to rapidly differentiate 
viruses.  
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2.6.0. Figure Legend: 
 
 
Figure 2.1. QIAxcel gel image of amplified products after multiplex RT-PCR of 
representative strains of the seven targeted swine viruses. Nucleic acid extracted from 
oral swabs taken from healthy pigs were used to access the specificity of the PCR. 
Asterisk represents the use of in vitro transcribed RNA, NTC: no template control. 
QIAxcel 50-3000 bp ladder was used in the program for analysis and 300-2000 bp 
markers are shown. 
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Figure 2.2. 1% agarose gel of seven target swine viruses in single-plex with unmodified 
primers (A) and TriLink CleanAmp™ primers (B). All single-plex reactions run with a 
no template control (NTC). Clinical negative sample extracted from swab material from a 
healthy pig. Ladder used was 1kb plus (Invitrogen, Burlington, ON). Asterisk represents 
transcribed RNA template. 
  
 
71 
 
 
72 
Figure 2.3. Gel electrophoresis images depicting validation RT-PCR of the seven-plex 
multiplex against a panel of 80 lab strains. (A) SYBR Safe agarose gel image of 23 
FMDV strains including at least two strains per the seven serotypes. (B) QIAxcel gel 
images depicting validation RT-PCR  of 12 SVDV, 10 CSFV, 1 VESV, 3 ASFV, 1 PCV 
2 and 8 PRRSV strains, (C) 11 clinical negative oral and nasal swab material with a 
spiked PRRSV YNL internal control and (D) 11 non-target swine virus and bacteria 
spiked with PRRSV YNL as an internal control. PRRSV YNL run as an internal control 
to test that the RT-PCR is working in non-specific samples. QIAxcel 50-3000 bp ladder 
was used in the program for analysis and 300-2000 bp markers are shown. 
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Figure 2.4.  Microarray bar graph showing RT-PCR products hybridized to specific 
capture probes utilizing the optimized NanoChip 400 protocol. Bars represent the ratio of 
positive fluorescent signal to negative (PN) or background signal from the NTC. Red line 
shows the PN cut off of 2, marking anything above the line as detected. 
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Figures 2.5. Seven-plex RT-PCR amplified viruses visualized using agarose gel and 
QIAxcel system (A.) and heat map depicting the reactivity of samples against 27 virus-
specific capture probes and one non-specific binding probe (NSBP) (B.). The panel of 
samples includes 58 strains of the seven targeted swine viruses, 11 oral swab samples 
taken from healthy pigs and 11 non-target virus and bacteria that are associated with 
livestock. The viral strains tested include representatives of each of the seven FMDV 
serotypes, three CSFV genotypes, two ASFV genotypes and two genotype linages of 
PRRSV, genotype 1 & 2. Scale legend shows positive signal in red that represents a 
positive to negative ratio (PN) of ≥ 2, while negative results in black represent any PN < 
2. 
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Figure 2.6. QIAxcel gel image of the amplification of SVDV ITL 19/99 10-fold serially 
diluted transcribed RNA by three RT-PCR tests: single-plex, seven-plex and five-plex 
(exotic). The three different RT-PCR tests show the effect of additional primers on 
amplification sensitivity. The positive control (+ctrl) used is a 1/50 dilution of SVDV 
ITL 19/99 RNA. NTC refers to a no template control. QIAxcel 50-3000 bp ladder was 
used in the program for analysis and 600-800 bp markers are shown. 
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Chapter 3. Integration of High Consequence Swine Virus Assay onto a Portable 
Sample-to-Answer Automated Detection System 
 
3.1.0. Introduction 
In todays market, there  is a need for more rapid and sensitive diagnostic testing 
for detecting pathogens causing foreign animal diseases (FAD). Introduction of FAD 
causing pathogens into a naïve ecosystem has the potential to cause devastating economic 
impacts, such as the 2001 foot-and-mouth disease (FMD) outbreak in the UK which 
resulted in $13 billion US in losses (Thompson et al. 2002) and the classic swine fever 
virus (CSFV) outbreak in the Netherlands in 1997-1998 that caused roughly $2 billion 
US in economic losses (Terpstra and de Smit 2000). Outbreaks like this are why 
organizations such as the World Organization of Animal Health, also known as the Office 
International des Epizooties (OIE), support the creation of internationally accepted 
control and prevention methods for highly contagious FADs (Pasick and Kahn 2014).  
Some major FAD viruses being targeted for control and prevention are: foot-and-
mouth disease virus (FMDV), swine vesicular disease virus (SVDV), vesicular 
exanthema of swine virus (VESV), CSFV and African swine fever virus (ASFV). These 
five FAD viruses are selected for control due to their highly infectious nature and because 
the diseases they cause are clinically indistinguishable signs from one another. An 
example of this is seen in the vesicular lesions produced by FMDV, SVDV and VESV. 
Vesicular lesions on the feet and mouth of all cloven hoofed animals are the main signs 
of all three viruses, yet because FMDV is the most infectious virus known, it is the 
priority for all diagnostic tests during an outbreak (Banér et al. 2007; Fernández et al. 
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2008; Lung et al. 2011). However, due to similar disease signs, diagnosis can be difficult. 
Other confounding pathogens that occur in Canada are porcine circovirus Type II (PCV 
2) and porcine reproductive and respiratory syndrome virus (PRRSV). This uncertainty in 
visual signs can result in reduced response times to implement quarantine procedures to 
isolate the outbreak, possibly allowing the pathogen to spread. Thus, a rapid and fully 
integrated and automated detection system is desirable for the simultaneous and accurate 
differentiation of all target pathogens. 
Current gold standard diagnostic detection tests for these pathogens include; virus 
isolation (VI), enzyme-linked immunosorbent assay (ELISA), virus neutralization and 
real time polymerase chain reaction (qPCR) (Table 3.1). These tests have been 
implemented due to their sensitivity and ability to diagnose diseases specifically. The 
problem with gold standard testing is that tests such as VI are labour intensive and 
require experienced technicians to complete and they require specific samples or cell 
lines to grow certain pathogens (Wu et al. 2013). Virus isolation is highly specific at 
diagnosing diseases but requires at least four days and specific cell lines to propagate the 
viruses (Yamazaki et al. 2013). ELISAs also have limitations in what samples can be run, 
including clotted blood and milk which cannot be used (S. Reid et al. 2003).   
Point-of-Care (POC) systems represent a novel solution to these issues by 
reducing manual hands-on time, transfer of material to centralized laboratories and wait 
times for results. Point-of-Care testing is the use of diagnostic tests that can be performed 
in close proximity to the patient using easily transported devices (Holland and Kiechle 
2005; S. Park et al. 2011). A POC system can combines multiple tests and devices (ie. 
Extraction, thermocycler and detection instruments) and bridges the gap between them by 
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offering an integrated instrument. Examples of such as combinations are the reverse 
transcription (RT) polymerase chain reaction (PCR) and capillary electrophoresis 
microchips (Kaigala et al. 2008), as well as the integrated sample extraction, PCR and 
detection microarray of the Rheonix CARD® (Spizz et al. 2012, 2015). The Clinical 
Laboratory Improvement Amendments of 1988 (CLIA’88) provide the guidelines for 
POC standards, as well as describe that for an assay to be a POC it must be classified as a 
“waived” or simple enough for untrained users to use without causing errors. Current 
nucleic acid testing methods have been classified as “highly complex” which means that 
tests such as RT-PCR or qPCR assays must be run in a laboratory by trained personnel 
for accurate results (Holland and Kiechle 2005; Niemz et al. 2011). Assays such as the 
POCKIT™, an insulated isothermal PCR (iiPCR), have been described in the detection of 
pathogens such as FMDV and CSFV. The described assay from Ambagala et al. (2016) 
and Lung et al. (2015) use the basic positive/negative results of the POCKIT™, an 
economic and portable instrument, to accurately detect FMDV (Ambagala et al. 2016) 
and CSFV (Lung et al. 2015) from clinical material. With platforms such as these, 
diagnosis can be made without having time consuming workflows and complex 
machinery. Having the ability to move the assay from the bench top to the onsite location 
of the suspected infection will help to mitigate possible contamination from over-
handling and sample degradation.  
Nexogen Inc. (San Diego, CA) has created a prototype POC sample-to-answer 
system that incorporates together magnetic bead-based nucleic acid extraction, reverse 
transcription PCR (RT-PCR) and carbon based microarray detection into a single 
contained unit. This medical diagnostics machine (MDx)  utilizes a single-use cartridge, 
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along with a fluorescent capturing system for visualization and automated systems. The 
system is contained within a portable container and utilizes a computer script, run off an 
accompanying laptop.  
The goal of this project is to transfer the seven-plex multiplex assay from 
Erickson et al. (2017) to Nexogen’s integrated and portable MDx system. Testing is split 
into 3 sections: Proof-of-concept, partial integration- Phase I and Phase II, and Phase III, 
full integration (Figure 3.1).   
 
3.2.0. Materials and Methods 
3.2.1. Samples 
 
For the transfer of the NanoChip 400 assay from Erickson et al. (2017), the same 
seven swine viruses (Table 3.2) were selected for testing in this study. A panel of eight 
viral strains was used for initial testing of the MDx assay components: FMDV SAT 3 
BEC 1/65, SVDV ITL 19/92, CSFV Alfort187, ASFV Lisbon 61, VESV Cal, PCV2 B, 
PRRSV YNL and PRRSV LV. Two lineages of PRRSV, North American (NA) and 
European (EU), were included to validate the ability of the assay to type and differentiate 
the two virus lineages. Initial testing was done with 1/50 dilutions of extracted viral RNA 
and DNA from available lab samples, as well as in house generated in vitro transcribed 
RNA for FMDV and CSFV. Most virus work was carried out in the level 3 biosafety 
laboratories at the Canadian Food Inspection Agency (CFIA) National Centre for Foreign 
Animal Disease (NCFAD) in Winnipeg, due to the biocontainment requirements for the 
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five exotic viruses, while work with the indigenous viruses was completed in the CFIA 
National Centre for Animal Disease (NCAD) Lethbridge Laboratory.  
A synthetic construct for FMDV SAT3 BEC 1-65 was made using the 981 base 
pair (bp) region encoding VP3/VP1/2A/2B portions of the polyprotein and used as a 
surrogate of viral RNA in assay development due to the absence of FMD viral RNA in 
Lethbridge. In vitro transcribed RNA was generated from plasmids cloned with DNA 
from FMDV synthetic constructs and CSFV plasmid containing the PCR target gene. For 
in vitro transcription of RNA, the MEGAscript® kit (Life Technologies – Invitrogen, 
Burlington, ON) was used. A reaction mix was made up for the in vitro transcription 
containing; 1 µg of plasmid, 2 µL of each 75 mM dNTP (ATP, GTP, CTP and UTP), 2 
µL of 10x reaction buffer, 2 µL enzyme mix and up to 7 µL nuclease-free water for a 
final volume of 20 µL. The in vitro transcription reaction continued for 4 hours at 37 °C. 
Template DNA was removed by digestion with 3 µL TURBO® DNase (2U/ µL, Life 
Technologies-Ambion, Burlington, ON) at 37 °C for 30 min. The transcribed RNA was 
purified using the RNeasy mini kit “RNA clean-up” protocol (Qiagen, Toronto, ON) as 
per the manufacturer’s specifications. Complete DNA removal was confirmed by PCR 
amplification of the digested material using a RT-PCR reaction with and without the RT 
component.  
The PCR conditions for the “with RT” reaction were as follows; A 50 µL RT-
PCR reaction, run with the SuperScript® III OneStep RT-PCR with Platinum Taq kit, 
consisted of 1 µL each of 1µM FMDV, CSFV and PCV2 primers (n=6) and 0.5 µL each 
of 0.5µM SVDV, VESV, ASFV and PRRSV primers (n=8), 25 µL of 2x RT buffer mix, 
2 µL of SSIII enzyme mix, 15 µL of ultra-pure water and 1 µL of template. The RT-PCR 
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reaction was processed on the Veriti thermal cycler (Life Technologies-Applied 
Biosystems, Burlington, ON) using the following conditions: 55°C for 15 min for RT, 
then 94°C for 2 min for initial denaturation, followed by 35 cycles of: denaturation at 
94°C for 30 min, annealing at 50°C for 1 min and extension at 68°C for 1 min followed 
by a 5 min final extension step at 68 °C.  
The “without RT reactions” were processed the same as the “with RT reactions: 
with the following differences:  amplification was preformed using Platinum® Taq DNA 
polymerase High Fidelity (Life Technologies - Invitrogen, Burlington, ON), 5 µL of 10x 
high fidelity buffer, 1 µL of dNTPs (10mM), 50mM MgSO4 0.2 µL of Platinum® Taq 
polymerase (5U/ µL), up to 50 µL of ultra-pure water and 1 µL of template RNA. The 
Veriti thermocycler conditions were the same as the “with RT” reaction, but with no RT 
step. RNA quantification was done using the Qubit® 2.0 Fluorometer system and RNA 
broad range kit (Life Technologies-Invitrogen, Burlington, ON). Copy number analysis 
was done using the following equation: 
 
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐(𝑐𝑐𝑛𝑛) 𝑥𝑥 6.022𝑥𝑥1023/𝑚𝑚𝑐𝑐𝑚𝑚𝑐𝑐
𝑏𝑏𝑐𝑐𝑏𝑏𝑐𝑐 𝑝𝑝𝑐𝑐𝑐𝑐𝑐𝑐(𝑏𝑏𝑝𝑝)𝑥𝑥 1𝑥𝑥109 𝑐𝑐𝑛𝑛 𝑛𝑛�  𝑥𝑥 𝑀𝑀𝑐𝑐𝑚𝑚𝑐𝑐𝑐𝑐𝑀𝑀𝑚𝑚𝑐𝑐𝑐𝑐 𝑊𝑊𝑐𝑐𝑐𝑐𝑛𝑛ℎ𝑐𝑐 𝑏𝑏𝑝𝑝 𝑛𝑛 𝑚𝑚𝑐𝑐𝑚𝑚𝑐𝑐�  
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3.2.2.0. MDx Sub-Component testing: 
 
Sub-component testing was done as proof-of-concept, showing the individual 
components ability to perform. All proof-of-concept tests were done on benchtop by hand 
using the same reagents and template as would be used in the MDx system. Alongside the 
benchtop work, a control PCR was run to help compare to the results taken from the 
extracted material (Figure 3.1A).  
 
3.2.2.1. MDx Nucleic Acid Extraction Sub-component 
 
To test the nucleic acid extraction sub-component, serial dilutions of virus stocks 
were made to test in the MDx cartridge extraction chemistry. PRRSV YNL passage 3 
virus stock was diluted to 1/100 in Phosphate Buffered Solution (PBS) pH of 7.5.  
For all virus cultures, nucleic acid extractions were done using a proprietary 
magnetic bead based extraction kit from Nexogen Inc. on the benchtop. Briefly, 200 µL 
of virus sample was added into 600 µL of magnetic bead containing Lysis buffer, 
vortexed for 20 s then incubated at room temperature for 1 min and centrifuged briefly. 
Beads were then collected using a magnet for 1 min after which supernatant was 
discarded. Beads were washed with 600 µL Wash buffer I (WBI), vortexed for 10 s and 
centrifuged briefly. Magnetic collection of the beads was repeated, after which the beads 
were washed with 600 µL of Wash buffer II (WBII). The solution was mixed gently and 
extracted similarly to WBI. Finally, the beads were resuspended in 50 µL of elution 
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buffer, vortexed for 10 s, centrifuged briefly, beads were collected by a magnet and the 
supernatant was collected and saved for testing on RT-PCR.  
 
3.2.2.2. Seven-plex RT-PCR Sub-component  
 
The seven-plex RT-PCR assay from Erickson et al. (2017) was transferred to the 
MDx RT-PCR tube for testing of the RT-PCR sub-component. Based on machine 
specifications, the 22 primer (Table 3.3) assay was modified from a 50 µL reaction to 
150µL to account for the addition of approximately 50 µL of elution material from the 
nucleic acid extraction sub-component of the MDx cartridge. Bench top testing of the 
RT-PCR assay used the following reagents: a 50 µL reaction with 0.25 µL each of 1µM 
final concentration of FMDV, CSFV and PCV2 primers (n=6) and 0.125 µL each of 0.5 
µM final SVDV, VESV, ASFV and PRRSV primers (n=8) all at a starting concentration 
of 200 µM, 25 µL of 2x RT buffer mix, 2 µL of SSIII enzyme mix, 19.5 µL of ultra-pure 
water and 1 µL of target sample. The 50 µL reaction was multiplied by 3 to get the 150 
reaction volume used in the MDx cartridge. The RT-PCR reaction was run on the Veriti 
thermal cycler at the following conditions: 55 °C for 22.5 min for RT, then 94 °C for 2 
min for initial denaturation, followed by 35 cycles of: denaturation at 94 °C for 30 s, 
annealing at 50 °C for 30 s and extension at 68 °C for 1 min and followed by a 5 min 
final extension at 68 °C. Post-amplification reactions were visualized using one of two 
methods: The QIAxcel (Qiagen, Toronto, ON) was used for all samples except for all 
FMDV samples in which agarose gel electrophoresis with SYBR® safe DNA gel stain 
(Life Technologies-Molecular Probes, Burlington, ON) was used in Winnipeg. 
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3.2.2.3. Electronic Carbon Detection Array and Statistical Analysis 
 
Proprietary carbon based microarrays with 100 hydrogel pads were tested using 
the selected capture probes (Table 3.4) transferred from Erickson et al. (2017). The 
probes were prepared to 10 uM in dH2O and then diluted to 9.5 uM in low salt buffer 
(LSB, Nexogen, Inc., San Diego, CA). Probes were spotted manually onto the 
streptavidin containing hydrogel that covers each of the 100 electrode pads. Briefly, the 
arrays were washed in LSB and then soaked in LSB for 15 min, washed thoroughly with 
dH2O and air dried completely before spotting. Select probes were spotted in triplicate 
onto the hydrogels, 0.35 µL per spot. Two spotting controls were introduced, 
fluorescence control and a reporter control. The reporter control is a probe that is 
sequence specific to the tag sequence use on the red universal reporter (RUR, 5`-
flurophore-TGTCAAGCGATATACTGC-3`) used to visualize that hybridization has 
occurred and that the RUR is annealing properly. The fluorescence control was used to 
indicate location as it will fluores during imaging. After spotting, the array was left at 
4°C for 1 hour in a moist container for probe hybridization. The array was washed with 
Hisproclin buffer containing: 50 mM Histidine (Sigma-Aldrich, St. Louis, MO) and 
0.05% proclin® 300 (Sigma-Aldrich-Supelco, Bellefonte, PA). Arrays were stored at 4°C 
in Hisproclin until needed. 
For capture probe screening, arrays were dried completely and a plastic flow cell 
and translucent cover was adhered to the array. The array was then attached to a 
“backend” cartridge designed to simulate the final stages of the full cartridge run. Liquid 
was pumped manually through a system of tubing and syringe. Amplicons were diluted 
3:1, to a final volume of 200 uL, in Cap Down A buffer (CdA, Nexogen, Inc., San Diego, 
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CA) and delivered to the array by a syringe. The RUR was diluted 1:100 to a final 
concentration of 0.25 uM, and 200 uL was added to the array and incubated for 7 min at 
room temperature. Electronic addressing of the reporter probe was performed on the 
MDx instrument at 1.6 nA for 2 min after which the array was incubated for 5 min. The 
array was washed with 200 uL of LSB at room temperature and LED lights were used to 
capture an image of the fluorescing probes using 5, 10, 15 and 20 s exposure time.  
Images were analyzed using Array-Pro Analyzer 6.3 (Media Cybernetics, 
Rockville, MD, US) software, measuring the level of fluorescence and extracting raw 
intensity values into an Excel spreadsheet. The values for the same probe (n=3) were 
averaged and standard deviations were determined. The standard deviations, divided by 
the average fluorescence and multiplied by 100%, were used to calculate the percent 
coefficient of variation (%CV). The %CV is being used to determine any samples than 
needed to be repeated. The %CV was determined for each probe and when values 
reached above 50-60% CV, the experiment was repeated. Final data was represented as a 
positive:negative ratio (PN) where all averaged probe values were divided by the average 
of the non-specific binding probe (NSBP).  
 
3.2.3.0. Integration of MDx Assay Sub-components: 
 
Integration of the sub-components was done in three phases: I, II, III. Phase I 
combines the nucleic acid extraction and RT-PCR steps while phase II combines the RT-
PCR and microarray components as seen in figure 3.1B and 3.1C respectively. These 
phases are done using the MDx instrument and cartridge controlled by the computer 
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scripts (Figure 3.2), but with hands on manipulation of the cartridge where needed. For 
example, stopping the run and fixing any errors as they occur or to modify the script 
based on visual observations. The final phase, III, is the full integration of all three 
components with little to no manual manipulation of the cartridge or the computer script 
(Figure 3.1D).  
 
3.2.3.1. Partial Integration Phase I: Nucleic acid extraction and RT-PCR 
 
Using a computer script supplied by Nexogen, with slight in-house modifications, 
complete prototype MDx cartridges were used to integrate the nucleic acid extraction 
procedure and RT-PCR step. A 150 µL RT-PCR reaction was set up and placed into the 
MDx PCR tube and attached to the cartridge at position C (Figure 3.2). A standard 50 µL 
reaction was set up and spiked with previously extracted DNA/RNA and placed on the 
Veriti thermocycler as a control. With a needle and syringe (Figure 3.2A) 300 µL of 
virus, diluted in 1/3 in PBS, was injected into the lysis chamber and sealed with hot glue. 
After the cartridge was inserted into the MDx instrument the computer script was 
initiated to start the automated nucleic acid extraction procedure where the sample is 
moved through each chamber of the MDx cartridge in succession (Figure 3.2B). At the 
end of the extraction, approximately 50 µL of eluted material is automatically transferred 
to the attached PCR tube, and added to the 150 µL of the seven-plex RT-PCR reaction 
mixture. The PCR reaction is carried out similarly to section 2.2.2. and after the run is 
completed the MDx and Veriti control amplicons were analyzed with the QIAxcel to 
compare the band sizes and intensities.  
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3.2.3.2. Partial Integration Phase II: RT-PCR and Carbon Detection Array 
 
A Nexogen computer script modified in-house was used to integrate the RT-PCR 
and microarray sub-components of the process in the cartridge. A 150 µL MDx RT-PCR 
reaction, spiked with 3 µL of extracted target DNA/RNA, was set up, loaded into the 
MDx PCR tube (Figure 3.2C) and placed into the MDx instrument. The MDx script ran 
the RT-PCR stage and after the PCR finished, the amplicon was automatically mixed 
with 300 µL of Sample Buffer A (SBA) and loaded onto the microarray (Figure 3.2D). 
Amplicons were electronically addressed to the carbon array at 1.6 nA for 2 min, paused 
for 5 min and hybridized to 500 µL of RUR reporter probe for 7 min. The array was then 
washed four times with 400 µL of LSB with an image taken after each wash using 
exposure times of: 5, 10, 15, and 20 s. 
  
3.2.3.3. Phase III: Full Integration of MDx Seven-plex Assay 
 
The full MDx computer script was used to integrate the entire three assay sub-
components: DNA/RNA extraction, RT-PCR and detection microarray. Integration of the 
three components was done similarly to the phase I partial integration, but removing the 
QIAxcel check immediately preceding to the RT-PCR and detection steps. The 
integration is done without any manual manipulation of either the script or cartridge.  
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3.3.0. Results 
3.3.1. Assay Sub-component, Proof-of-Concept Testing 
 
A seven-plex RT-PCR amplicon-to-answer assay was transferred from the 
NanoChip 400 electronic microarray platform, to the prototype fully automated and 
integrated “sample-to-answer” MDx platform. The MDx assay was broken down into 
three subcomponents and evaluated separately before integrating the components 
together. A panel of the seven target viruses was used to test the three assay components: 
nucleic acid extraction, RT-PCR and detection microarray. For testing of the nucleic acid  
extraction sub-component, the nucleic acid extracting chemistry kit supplied by Nexogen 
was used. Nucleic acid extraction of all 7 target viruses was successfully extracted offline 
on the bench top, off the MDx instrument, from cell culture material and amplified using 
the standard RT-PCR from Erickson et al. (2017) (Figure 3.3). For testing of the 
PCR/RT-PCR sub-component, total nucleic acid from the target viruses were amplified 
using the MDx thermocycling module in a MDx cartridge on a MDx instrument (Figure 
3.4). Resulting amplicons were compared to control amplicons generated using the 
Erickson et al. (2017) assay, and showed similar amplification (data not shown). To test 
the microarray detection sub-component, amplicons generated from the offline Veriti 
thermocycler were applied to the carbon array and run through the hybridization and 
washing protocols on a MDx cartridge, where all seven amplicons bound to their specific 
probes (Figure 3.5). 
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3.3.2. Partial Integration 
 
After demonstrating and establishing proof-of-concept of the MDx sub-
component parts, the assay was moved into the partial integration step, Phase I. Phase I of 
the integration included integration of nucleic acid extraction and RT-PCR on the 
microfluidic cartridge. Nucleic acid were extracted from lab grown viruses  and amplified 
by RT-PCR using an MDx cartridge and amplicons were visualized on QIAxcel. 
Amplicons from all seven viruses were detected indicating successful nucleic acid 
extraction and RT-PCR amplification (Figure 3.6). Phase II integration of RT-PCR with 
microarray detection demonstrated that using pre-extracted nucleic acid, RT-PCR can be 
completed and amplicons can be detected by capture probes on the microfluidic cartridge 
automatically. Four out of seven target virus were detected by their respective probes: 6/7 
probes for SVDV, 2/2 for VESV, 1/2 for PCV 2 and 3/5 for PRRSV YNL (Figure 3.7). 
Three of the seven targets; FMDV, CSFV and ASFV failed to be detected.   
 
3.3.3. Full Integration 
 
A total of 300 uL of laboratory amplified virus were diluted 1:3 in PBS for testing 
of the fully integrated assay. All target viruses were run from beginning to end using the 
automated computer program, without any manual manipulations. Four of the seven 
targets, SVDV, VESV, PCV 2 and PRRSV YNL and LV, were run from beginning to 
end and detected by their specific probes. The four targets were successfully extracted, 
amplified by RT-PCR (Figure 3.8a) and detected on their respective capture probes 
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(Figure 3.8b) fully automated on the microfluidic cartridge. FMDV, CSFV and ASFV 
failed to amplify after extraction, resulting in no detection. 
 
3.4.0. Discussion 
 
The objective of this project was to transfer a previously developed and optimized 
assay (Erickson et al. 2017) to a new prototype, fully automated and integrated “sample-
to-answer” microarray detection platform.  
Transfer of the assay was accomplished by first testing the individual assay sub-
components that make up the “sample-to-answer” system: Nucleic acid extraction, RT-
PCR and detection by carbon microarray. Each sub-component was tested with the seven 
target viruses, as well as the European serotype for PRRSV (Table 3.2). The extraction 
chemistry kits supplied by Nexogen Inc. (San Diego, USA) contained all of the reagents 
required for extracting nucleic acid from virus samples on the MDx microfluidic 
cartridge. Though offline testing was done to mimic the nucleic acid extraction on the 
MDx cartridge, there were differences between the offline and on-cartridge processes. 
For example, samples were vortexed rigorously on a stand alone vortex instrument to 
ensure proper mixing of sample and reagents offline, while the cartridge uses a syringe to 
mix the reaction components 10 times. Though both samples are mixed, the more 
vigorous mixing offline may aid in cell lysis and washing, allowing for better nucleic 
acid extraction and result in a stronger signal to noise ratio than the automated cartridge 
system. Similarly, testing of the carbon microarray offline manually allowed for greater 
control of the movement of liquids. Thus, if pressure is lost or a leak was observed due to 
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quality of the prototype cartridge, more liquid can be immediately introduced manually to 
compensate. Therefore the results show a successful transfer and proof that the individual 
assay components are compatible with the target viruses and the prototype MDx.  
In the process of fully automating the assay, the individual sub-components were 
systematically integrated together. Phase I (integration of nucleic acid extraction and RT-
PCR) worked well for all the targets, but phase II (integration of RT-PCR and microarray 
detection) had issues with detection of three targets. Four of the targets viruses were 
successfully detected automatically demonstrating the integrated system works. However, 
manufacturing quality control issues (ie. leaks) and coding errors with computer coding 
contributed to the failure of the FMDV, CSFV and ASFV targets being amplified by RT-
PCR and detected. In many runs, little to no amplification was seen after spiking the 
MDx PCR tube with template DNA/RNA as input material, despite the positive controls 
ran successfully offline in a thermocycler (data not shown). The temperature of the MDx 
RT-PCR reaction can be monitored on a peltier interface graph showing Time vs. 
Temperature. Issues with failure to reach set temperatures or took too long time to reach 
temperature is frequently observed (data not shown). This is the most likely reason for 
the weak or no amplification after RT-PCR that was observed.  
Fully automated and integrated detection was achieved for four of the seven 
viruses, SVDV, VESV, PCV 2 and PRRSV. During full integration, extraction 
efficiencies of FMDV and CSFV in cell culture media were low, most likely due to low 
sample titre. However, one experiment showed that ASFV was successfully extracted and 
amplified by PCR on the MDx cartridge, but was not detected due to a manufacturers 
defect in the microfluidics going onto the microarray of the cartridge (data not shown). 
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Amplicon size may have attributed to FMDV and CSFV failing to amplify after 
extraction. FMDV and CSFV are two of the larger amplicons in the assay at around 980 
and 650 bp respectively. Though, with SVDV reacting strongly, low titre of the available 
lab virus may be the reason for the failed detection. 
Replication of the results was a major issue during the move to the MDx. The 
MDx is a second generation prototype instrument and during the development process 
multiple instrument and cartridge errors occurred. About 66 full cartridges were used to 
generate results, however only a portion of them yielded usable results. Due to these 
inconsistences a true comparison between the NanoChip 400 and the MDx was not 
completed. Though four of the seven viruses were successfully run on the fully integrated 
MDx, the assay couldn’t be truly validated due to the missing viruses and the low 
reproducibility of the system. More work on the MDx would be needed to address these 
issues.   
Fully automated and integrated sample-to-answer pathogen detection is a 
powerful concept for rapid POC diagnostics with the potential application in hospitals, 
clinics or farms. Since outbreaks can happen suddenly and spread fast, such as the 2001 
UK FMDV outbreak (Thompson et al. 2002), it is imperative that veterinarians and 
inspectors have the ability to rapidly diagnose and implement quarantine zones around 
infected herds to contain the spread of the pathogen. Nexogen's advanced prototype MDx 
machine represents a novel way of filling this niche. Its fully integrated design and 
portable instrumentation makes it a potentially useful tool that can be used for on-site 
detection. Other types of POC devices partially integrated the full workflow. For 
example, the JANUS automated workstation incorporates sample extraction to qPCR 
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(Vandemeulebroucke et al. 2010).  PCR to detection POC devices can be a simple as a 
lab-on-chip mounted to a self-made electronics board (Tan et al. 2014) or the VereFluTM 
lab-on-chip system that incorporates a standalone PCR/microarray instrument and reader 
system (Teo et al. 2011). The MDx instrument goes beyond these other instruments by 
integrating together sample extraction, RT-PCR and microarray detection to create a 
simple user-friendly diagnostic tool that technicians can use with minimal training.  
Future directions for this project include further validation of this POC 
technology. The advanced MDx prototype instrument and cartridge used in this project is 
undergoing further refinement to improve manufacturing reproducibility and fix 
computer coding errors. As part of the optimization undertaken in this project, utilizing 
higher RT temperatures and by altering the computer scripts manually to allow longer 
incubations or mixing steps improved results. Nexogen has also announced the 
development of new systems such as the Nexi-Dx, a card based sample-to-answer system 
or the CAS-100, a three cartridge sample-to-answer system that uses the same cartridge 
system as the MDx (http://dhodko5.wixsite.com/mysite). Systems such as these are the 
future for the POC industry.  
To conclude, the seven-plex multiplex assay from Chapter 2 was successfully 
transferred from the NanoChip 400 electronic microarray to Nexogen's prototype fully 
integrated and portable MDx instrument. Proof-of-concept was achieved by successfully 
extracting, amplifying and detecting a seven viruses on each of the instruments individual 
sub-components as well as for partial integration. Full, hands off, integration of the 
seven-plex assay was demonstrated for four of the seven viruses, including two lineages 
for PRRSV (NA and EU).  
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3.6.0. Figure Legend 
 
 
Figure 3.1. Work flow chart illustrating the phases of development for the MDx 
detection assay. Samples are run manually on the benchtop using the same 
chemistry/conditions and microfluidic cartridge as would be run on the MDx instrument 
(i). A control PCR, using total nucleic acid extracted using Qiagen kit, was run along side 
the MDx PCR on a thermocycler (ii) for comparison (A). The extraction and RT-PCR 
components were integrated and tested on the MDx instrument using a MDx cartridge (i). 
A control RT-PCR was run along side on a Veriti Thermocycler (ii) for comparison (B). 
The RT-PCR and microarray components were integrated using previously extracted 
nucleic acid, with amplification and subsequent detection run on the MDx instrument (C). 
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All components were integrated together and samples run on the MDx instrument from 
nucleic acid extraction to detection with very little or no manual handling of the cartridge 
(D). 
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Figure 3.2. Schematic diagram of the prototype MDx cartridge for sample-to-answer 
detection. A sample injection needle (A) is used to allow the MDx instrument to transfer 
the sample into the nucleic acid extraction chamber (B). After nucleic acid extraction is 
complete, the eluted product is transferred using microfluidic channels to the PCR tube 
(C), that is inserted into the MDx thermocouple, where the extracted total nucleic acid is 
amplified. Amplicons are then transferred via microfluidic channels to the carbon 
microarray (D) where amplicons hybridize to immobilized capture probes and are 
detected using reporter oligonucleotides probes tagged with fluorophores. Schematic 
supplied by Nexogen Inc. (San Diego, California). 
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Figure 3.3. QIAxcel gel image of amplification of swine virus targets extracted using 
MDx extraction chemistry on the benchtop manually and amplified using standard RT-
PCR on a thermocycler. Lab propagated virus were used for extraction and amplification. 
No template control (NTC) was included as a negative control. QIAxcel 50-3000 bp 
ladder was used in the program for analysis and 400-1600 bp markers are shown. 
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Figure 3.4. QIAxcel gel image of proof-of-concept amplification of swine virus targets 
using thermocycling module on the MDx cartridge. Standard extracted material were 
used for amplification. Non-target BVDV RNA were included to demonstrate assay 
specificity. QIAxcel 50-3000 bp ladder was used in the program for analysis and 200-
1600 bp markers are shown. Asterisk represents the use of transcribed RNA as template 
material.   
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Figure 3.5. Proof-of-concept testing of RT-PCR amplicons on the MDx cartridge carbon-
based microarray. (A) QIAxcel gel image and (B) microarray heatmap of offline 
generated amplicon (Veriti thermocycler) run on a MDx cartridge. Nucleic acid extracted 
from lab propagated virus was used in the RT-PCR. Scale legend shows positive to 
negative (PN) ratios. Positive ratios of ≥ 2 are represented in red, while negative ratios 
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shown in black are a PN ratio of < 2. Non-specific binding probe (NSBP) used as a 
negative control probe.  
 
Figure 3.6. Gel images of phase I partial integration of the nucleic acid extraction and 
RT-PCR. (A) QIAxcel gel image and (B) SYBR Safe Agarose gel RT-PCR generated 
amplicons. Lab propagated viruses extracted and amplified automatically using the MDx 
cartridge. Amplicons generated with no manual manipulation of the MDx instrument. 
QIAxcel 50-3000 bp and SYBR Safe 1kb plus ladder were used. The 400-1600 bp 
markers are shown.  
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Figure 3.7. Phase II partial integration of MDx RT-PCR and microarray detection sub-
components using MDx instrument and cartridge. QIAxcel gel image (A) and microarray 
heatmap (B) of phase II partial integration. Nucleic acid extracted off instrument from lab 
propagated virus were used to produce amplicons Scale legend shows positive to negative 
(PN) ratios. Positive ratios of ≥ 2 are represented in red, while negative ratios shown in 
black are a PN ratio of < 2. Non-specific binding probe (NSBP) is used to determine the 
background signal from non-specific binding.   
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Figure 3.8. Phase III full integration of all MDx sub-components. QIAxcel gel image (A) 
and microarray heatmap (B) of full integration of the MDx. Lab propagated virus 
material was used as input into the MDx cartridges. All samples were extracted and 
detected on the microarray with no manual manipulation of the computer script or 
cartridge. Scale legend shows positive to negative (PN) ratios. Positive ratios of ≥ 2 are 
represented in red, while negative ratios shown in black are a PN ratio of < 2. Non-
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specific binding probe (NSBP) is used to determine the background signal from non-
specific binding.  
 
117 
3.7.0. References 
 
Ambagala, A., M. Fisher, M. Goolia, C. Nfon, T. Furukawa-Stoffer, R. Ortega Polo, and 
O. Lung. 2016. “Field-Deployable Reverse Transcription-Insulated Isothermal 
PCR (RT-IiPCR) Assay for Rapid and Sensitive Detection of Foot-and-Mouth 
Disease Virus.” Transboundary and Emerging Diseases 64 (5): 1610–23. 
https://doi.org/10.1111/tbed.12554. 
Banér, Johan, Péter Gyarmati, Alia Yacoub, Mikhayil Hakhverdyan, Johan Stenberg, 
Olle Ericsson, Mats Nilsson, Ulf Landegren, and Sándor Belák. 2007. 
“Microarray-Based Molecular Detection of Foot-and-Mouth Disease, Vesicular 
Stomatitis and Swine Vesicular Disease Viruses, Using Padlock Probes.” Journal 
of Virological Methods 143 (2): 200–206. 
https://doi.org/10.1016/j.jviromet.2007.03.004. 
Erickson, A., M. Fisher, T. Furukawa-Stoffer, A. Ambagala, D. Hodko, J. Pasick, D. P. 
King, C. Nfon, R. Ortega Polo, and O. Lung. 2017. “A Multiplex Reverse 
Transcription PCR and Automated Electronic Microarray Assay for Detection and 
Differentiation of Seven Viruses Affecting Swine.” Transboundary and Emerging 
Diseases, November. https://doi.org/10.1111/tbed.12749. 
Fernández, Jovita, Montserrat Agüero, Luis Romero, Carmen Sánchez, Sándor Belák, 
Marisa Arias, and José Manuel Sánchez-Vizcaíno. 2008. “Rapid and Differential 
Diagnosis of Foot-and-Mouth Disease, Swine Vesicular Disease, and Vesicular 
Stomatitis by a New Multiplex RT-PCR Assay.” Journal of Virological Methods 
147 (2): 301–11. https://doi.org/10.1016/j.jviromet.2007.09.010. 
Holland, Carol A, and Frederick L Kiechle. 2005. “Point-of-Care Molecular Diagnostic 
Systems — Past, Present and Future.” Current Opinion in Microbiology 8 (5): 
504–9. https://doi.org/10.1016/j.mib.2005.08.001. 
Huang, Ying, Huong Tang, Stuart Duffy, Yuwen Hong, Sylvia Norman, Madhu Ghosh, 
Jie He, et al. 2009. “Multiplex Assay for Simultaneously Typing and Subtyping 
Influenza Viruses by Use of an Electronic Microarray.” Journal of Clinical 
Microbiology 47 (2): 390–96. https://doi.org/10.1128/JCM.01807-08. 
Kaigala, Govind V., Viet N. Hoang, Alex Stickel, Jana Lauzon, Dammika Manage, Linda 
M. Pilarski, and Christopher J. Backhouse. 2008. “An Inexpensive and Portable 
Microchip-Based Platform for Integrated RT–PCR and Capillary 
Electrophoresis.” The Analyst 133 (3): 331. https://doi.org/10.1039/b714308g. 
Lung, O., J. Pasick, M. Fisher, C. Buchanan, A. Erickson, and A. Ambagala. 2015. 
“Insulated Isothermal Reverse Transcriptase PCR (iiRT-PCR) for Rapid and 
Sensitive Detection of Classical Swine Fever Virus.” Transboundary and 
Emerging Diseases 63 (5): 395–402. https://doi.org/10.1111/tbed.12318. 
 
118 
Lung, Oliver, Mathew Fisher, Anne Beeston, Kimberley Burton Hughes, Alfonso 
Clavijo, Melissa Goolia, John Pasick, William Mauro, and Dirk Deregt. 2011. 
“Multiplex RT-PCR Detection and Microarray Typing of Vesicular Disease 
Viruses.” Journal of Virological Methods 175 (2): 236–45. 
https://doi.org/10.1016/j.jviromet.2011.05.023. 
Niemz, Angelika, Tanya M. Ferguson, and David S. Boyle. 2011. “Point-of-Care Nucleic 
Acid Testing for Infectious Diseases.” Trends in Biotechnology 29 (5): 240–50. 
https://doi.org/10.1016/j.tibtech.2011.01.007. 
OIE - World Organization for Animal Health. 2018. “Manual of Diagnostic Tests and 
Vaccines for Terrestrial Animals.” OIE - World Organization for Animal Health. 
2018. http://www.oie.int/standard-setting/terrestrial-manual/access-online/. 
Park, Seungkyung, Yi Zhang, Shin Lin, Tza-Huei Wang, and Samuel Yang. 2011. 
“Advances in Microfluidic PCR for Point-of-Care Infectious Disease 
Diagnostics.” Biotechnology Advances 29 (6): 830–39. 
https://doi.org/10.1016/j.biotechadv.2011.06.017. 
Pasick, John, and S. Kahn. 2014. “The Scientific Rationale for the World Organisation 
for Animal Health Standards and Recommendations on Avian Influenza.” Revue 
Scientifique et Technique (International Office of Epizootics) 33 (3): 691–709. 
Reid, SM, SS Grierson, NP Ferris, GH Hutchings, and S Alexandersen. 2003. 
“Evaluation of Automated RT-PCR to Accelerate the Laboratory Diagnosis of 
Foot-and-Mouth Disease Virus.” Journal of Virological Methods 107 (2): 129–39. 
https://doi.org/10.1016/S0166-0934(02)00210-0. 
Spizz, Gwendolyn, Zongyuan Chen, Peng Li, I. Cristina McGuire, Paulina Klimkiewicz, 
Devin Zysling, Rubina Yasmin, et al. 2015. “Determination of Genotypes Using a 
Fully Automated Molecular Detection System.” Archives of Pathology & 
Laboratory Medicine 139 (6): 805–11. https://doi.org/10.5858/arpa.2014-0059-
OA. 
Spizz, Gwendolyn, Lincoln Young, Rubina Yasmin, Zongyuan Chen, Travis Lee, 
Deborah Mahoney, Xun Zhang, et al. 2012. “Rheonix CARD® Technology: An 
Innovative and Fully Automated Molecular Diagnostic Device.” Point of Care: 
The Journal of Near-Patient Testing & Technology 11 (1): 42–51. 
https://doi.org/10.1097/POC.0b013e318222e184. 
Tan, Jeslin J. L., Monica Capozzoli, Mitsuharu Sato, Wanitda Watthanaworawit, Clare L. 
Ling, Marjorie Mauduit, Benoît Malleret, et al. 2014. “An Integrated Lab-on-Chip 
for Rapid Identification and Simultaneous Differentiation of Tropical Pathogens.” 
Edited by Maya Williams. PLoS Neglected Tropical Diseases 8 (7): e3043. 
https://doi.org/10.1371/journal.pntd.0003043. 
Teo, Jeanette, Patrizia Di Pietro, Floriana San Biagio, Monica Capozzoli, Yi-Mo Deng, 
Ian Barr, Natalie Caldwell, et al. 2011. “VereFluTM: An Integrated Multiplex RT-
PCR and Microarray Assay for Rapid Detection and Identification of Human 
 
119 
Influenza A and B Viruses Using Lab-on-Chip Technology.” Archives of Virology 
156 (8): 1371–78. https://doi.org/10.1007/s00705-011-0999-7. 
Terpstra, C, and A.J de Smit. 2000. “The 1997/1998 Epizootic of Swine Fever in the 
Netherlands: Control Strategies under a Non-Vaccination Regimen.” Veterinary 
Microbiology 77 (1–2): 3–15. https://doi.org/10.1016/S0378-1135(00)00252-2. 
Thompson, D, P Muriel, D Russell, P Osborne, A Bromley, M Rowland, S Creigh-Tyte, 
and C Brown. 2002. “Economic Costs of the Foot and Mouth Disease Outbreak in 
the United Kingdom in 2001.” Revue Scientifique et Technique (International 
Office of Epizootics) 21 (3): 675–87. 
Vandemeulebroucke, Elise, Kris De Clercq, Yves Van der Stede, and Frank 
Vandenbussche. 2010. “A Proposed Validation Method for Automated Nucleic 
Acid Extraction and RT-QPCR Analysis: An Example Using Bluetongue Virus.” 
Journal of Virological Methods 165 (1): 76–82. 
https://doi.org/10.1016/j.jviromet.2010.01.007. 
Wu, Ling, Longfei Ding, Zenglin Pei, Xixiang Huo, Guoyuan Wen, and Zishu Pan. 2013. 
“A Multiplex Reverse Transcription-PCR Assay for the Detection of Influenza A 
Virus and Differentiation of the H1, H3, H5 and H9 Subtypes.” Journal of 
Virological Methods 188 (1–2): 47–50. 
https://doi.org/10.1016/j.jviromet.2012.11.032. 
Yamazaki, Wataru, Valérie Mioulet, Lee Murray, Mikidache Madi, Takeshi Haga, 
Naoaki Misawa, Yoichiro Horii, and Donald P. King. 2013. “Development and 
Evaluation of Multiplex RT-LAMP Assays for Rapid and Sensitive Detection of 
Foot-and-Mouth Disease Virus.” Journal of Virological Methods 192 (1–2): 18–
24. https://doi.org/10.1016/j.jviromet.2013.03.018. 
Zimmerman, Jeffrey J, Locke A Karriker, Alejandro Ramirez, Kent J Schwartz, and 
Gregory W Stevenson. 2012. Diseases of Swine. 10th ed. Chichester, West 
Sussex; Ames, Iowa: Wiley-Blackwell. 
  
 
120 
Chapter 4. Conclusions and Future Directions 
 
4.1.0. Conclusions 
 
The objective of this thesis was to develop, optimize and then transfer a multiplex 
RT-PCR and microarray assay on the NanoChip 400 electronic microarray to the new 
MDx system. Using multiplex RT-PCR technology, a seven-plex multiplex RT-PCR 
assay was developed, validated and incorporated into a corresponding NanoChip 400 
assay. It was shown that all samples tested (n=58) amplified and reacted to their 
appropriate capture probe while negative clinical samples (n=11) and non-target (n=11) 
samples were un-reactive. The NanoChip 400 assay was then successfully transferred to a 
proto-type fully integrated and portable, MDx, electronic microarray system. The MDx 
was successful in automatically performing nucleic acid extraction, RT-PCR 
amplification and detecting four of the seven high consequence viruses with no manual 
manipulations of the machine or cartridge. 
These two microarray systems, the NanoChip 400 and MDx, represent novel user-
friendly detection platforms. Their ease of use simplifies user training needed to conduct 
multiplex diagnostic tests in both the laboratory and in the point of need. “Point-of-care” 
(POC) instruments are desirable as it allows detection on-site, eliminating the need for 
transport of samples.  
Many examples exist where delayed diagnosis has caused greater damage, as in 
the case of the foot-and-mouth disease (FMD) outbreak in 2001 for the UK (Thompson et 
al. 2002). FMD is the most contagious animal virus known and can spread very quickly, 
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affecting thousands of animals in a matter of days. After the outbreak was identified and 
contained about 6.5 million animals, infected or not, were culled to halt the spread of the 
virus. The UK suffered an estimated $13 billion loss to its economy (Thompson et al. 
2002). Another example of a viral disease slipping through surveillance was the 1997 
outbreak of classical swine fever (CSF) in the Netherlands. This outbreak affected around 
1.1 million pigs, which were culled to prevent spread of the disease causing pathogen 
(Terpstra and de Smit 2000). In more recent news, the OIE reported in their annual 
reports that there has been an outbreaks of African swine fever virus (ASFV) in Europe, 
Africa and China. They report that as of March 28, there have been a loss of nearly 3000 
pigs, approximately 97% being from Asia, due to the ASFV outbreak 
(http://www.oie.int/fileadmin/Home/esp/Animal_Health_in_the_World/Report_13_Curre
nt_situation_of_ASF.pdf). Due to the high risk of pathogen spread, it is imperative that 
rapid and user-friendly diagnostic tests be developed to reduce the time needed for 
disease diagnosis.  
The NanoChip 400 is a potentially useful addition to a diagnostic laboratory. Its 
400 test sites can be independently activated by platinum electrodes to allow negatively 
charged amplicons to be attracted to test sits for instantaneous hybridization. Thus results 
are obtained in a few hours compared to the gold standard virus isolation tests that can 
take a few days to generate results. Although the NanoChip 400 can readily produce 
results, size makes it more suitable for use in a lab. This as well as the fact that it requires 
the samples to be processed for nucleic acid extraction and PCR separately, makes it 
more of a laboratory instrument. The MDx, however, does fall into the category of a POC 
instrument. Its fully integrated design allows for the user to take it to the site of any 
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possible outbreak where the instrument can perform the entire process automatically and 
generate results in under three hours. Being a proto-type instrument, the MDx and its 
cartridges needs further development before commercialization.  
In conclusion, this applied thesis has covered the development, optimization and 
validation of a seven-plex RT-PCR multiplex assay and corresponding user-friendly 
electronic DNA microarray system for the detection and differentiation of five exotic and 
two indigenous swine viruses. The assay was successful at detecting all seven viruses 
from clinical material and with high sensitivity. The seven-plex assay was then 
successfully transferred to a fully integrated and portable machine, where it achieved 
detection of five out of seven viruses under complete automation from extraction to 
microarray detection.   
 
4.2.0. Future Directions 
 
The seven-plex RT-PCR multiplex and corresponding Nanochip 400 and MDx 
systems are potentially useful tools in molecular diagnostics of livestock diseases. Once 
the systems are fully validated and recognized as true diagnostic tests, the assays could be 
employed as a tool for inspectors in the fight to safeguard our food supply and livestock 
industry. Both laboratory technicians and veterinarians can be trained to use the 
technology to rapidly confirm possible viral outbreaks as well as being able to quickly 
implement quarantine of affected herds to halt the spread of the disease. Another positive 
attribute of the assays is that it can greatly reduce the number of animals that have to be 
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culled. It can do this by reducing test times for animals suspected of being infected, 
thereby allowing for animals that would have been killed otherwise in a blanket attempt 
to halt the spread of the disease. 
Future directions for this project are a two fold answer. One avenue is to do 
further optimizations on the system in an attempt to increase the sensitivity. One such 
optimization is to reduce the amplicon size of the larger targets such as FMDV, which 
sits at 981 bp. Doing this could aid in amplification of multiple targets simultaneously, by 
theoretically allowing the polymerase to amplify target genomic regions with little 
competition or size biasing. A full validation of multiple infections is needed for this 
assay. This would require a panel of different combinations of the seven high 
consequence viruses, from two to all seven. The number of combinations is very large so 
it would need to be worked down to the most likely combinations, PCV2 and/or PRRSV 
used as a base infection as they are found in pigs under healthy conditions. With the 
baseline viruses the combinations would be as follows: vesicular viruses  FMDV, SVDV 
and/or VESV and then the hemorrhagic viruses CSFV and ASFV. The resulting 
amplicons would then be run on the NanoChip 400 microarray to determine the efficacy 
of the assay in detecting multiple infections. Along with this, a second validation trial is 
needed to run more strains of the target viruses. In chapter 2, 58 samples are validated 
against the multiplex. Of those 58 only three were PRRSV isolates and three more were 
ASFV. A greater cateloge of isolates is needed to truly validate the assay.   
The other future direction for this project would be to continue testing the MDx 
instrument or moving to a more advanced system. The MDx instrument used in this 
thesis was a second generation prototype. Being that it was a prototype instrument there 
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were many mechanical issues that needed to be fixed and worked through. Having a 
system where the instruments and reagents are reliable is crucial. During the work on the 
MDx, only a small number of runs were completed due in part to the instruments repair 
status and the location of the samples needed to run in the assay. The adaptation of the 
NanoChip 400 assay to the MDx required the work to be done in a BSL-2 laboratory 
where only transcribed RNA and plamid constructs could be used in place of their BSL-3 
viral counterparts. The true virus work for five of the seven viruses had to be carried out 
in the BSL-3 laboratory in Winnipeg. In the BSL-3 labs, FMDV, SVDV, VESV, CSFV 
and ASFV viruses were run under high containment protocols, requiring them to be run 
in a special room where tubes being removed had to be soaked in Virkon S dissinfecant 
and people were required to shower out. This made any rapid progress difficult and when 
errors occurred, full days of work would be lost. Compounding the location and 
instrument issues, work on detecting these viruses requires meticulous planning and 
execution. More time working on the MDx system is the most important step in 
developing a reliable assay.     
As stated previously, the NanoChip 400s size made it more suitable for use in a 
laboratory. Recently, SavionDiagnostics (Ashdod, Israel) has developed an updated 
version of the previous NanoChip 400 instrument, the NanoChip 400 XL. The XL series 
is a smaller version of its predecessor, including in its design the capability to run PCR 
on the instrument. The addition of the PCR component allows for a more rapid and 
streamline processing of diagnostic samples, reducing the need for training on multiple 
instruments. SavionDiagnostics currently only offers NanoChip 400 kits for human 
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diseases and genetic mutation identification but they are in the process of adding 
veterinary diagnostic kits to their repertoire.   
The next step for the seven-plex multiplex assay is to incorporate additional new 
targets and upcoming technologies such as the POCKIT (Balasuriya et al. 2014; Lung et 
al. 2015; Ambagala et al. 2016), TwistDx (H. Liu et al. 2017; Garrido-Maestu et al. 2018) 
and the Rheonix system (Spizz et al. 2012, 2015; Z. Chen and Zhu 2016; Z. Chen et al. 
2013). The greatest ability of the multiplex assay described is that it can be altered easily 
to incorporate different targets such as bacteria. Another multiplex assay developed by 
Lung 2015 is used to identify eight targets of the Porcine Respiratory Disease Complex; 
four viruses and four bacterium that commonly infect pigs (Lung et al. 2015). Of the 
upcoming pieces of technology, the isothermal system found both the POCKIT and 
TwistDx represent a breakthrough in the development of POC instrumentation. 
Isothermal PCR utilizes one constant temperature to amplify gene products either using 
the insulated isothermal PCR method (iiPCR, POCKIT) or the recombinase PCR 
amplification (RPA, TwistDx) for detecting a single target (H. Liu et al. 2017; Garrido-
Maestu et al. 2018). The iiPCR uses a small tube that is heated at the bottom to around 95 
°C. This heating then causes a gradient of 95-60 °C (bottom-top) to form in the liquid and 
generates a small current that brings the DNA target into the different temperature areas, 
where it follows the steps of PCR amplification: At the bottom the DNA is denatured, at 
the top the primers anneal and in the middle it begins extension (Ambagala et al. 2016; 
Lung et al. 2015). For the TwistDx, the RPA method uses a low temperature, around 37 
°C, but utilizes recombinase proteins to help with primer binding and double helix 
denaturing (Swift et al. 2016). The major advantage to using these instruments is the 
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speed at which they can generate amplicons. Using one temperature means that there are 
fewer waiting steps involved where the thermocycler needs to either heat or cool to a 
specific temperature. The lack of a thermocycler also makes the system less expensive as 
it only needs a heating block that reaches one temperature, instead of fluctuating between 
multiple temperatures over time. 
The Rheonix Encompass MDx system represents what the Nexogen MDx system 
could possibly become in the future. The Encompass MDx is a fully automated system 
that utilizes the Rheonix CARD® (Chemistry and Reagent Device) that is controlled by 
microfluidics and air pressure. The Rheonix CARD® have already been used in human 
medicine applications, such as assays for sexually transmitted diseases (Spizz et al. 2012) 
and a Warfarin genotyping assay (Spizz et al. 2012, 2015) and has already had veterinary 
applications for livestock pathogens (Lung et al 2018).    
In the end, the purpose of these tools is to safeguard our environment and 
economy. Surveillance is the ultimate goal of projects such as these; creating new 
procedures and utilizing novel tools or techniques in ways that can detect pathogens 
faster or at lower titres than before. At the speed at which pathogens mutate and evolve, 
applied research such as the use of the NanoChip 400 and the Nexogen MDx has become 
indispensable to the protection of not only our personal health, but also the health of our 
livestock and economy.  
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